WO2021227906A1 - 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途 - Google Patents

一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途 Download PDF

Info

Publication number
WO2021227906A1
WO2021227906A1 PCT/CN2021/091707 CN2021091707W WO2021227906A1 WO 2021227906 A1 WO2021227906 A1 WO 2021227906A1 CN 2021091707 W CN2021091707 W CN 2021091707W WO 2021227906 A1 WO2021227906 A1 WO 2021227906A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
reaction
ethyl acetate
cancer
room temperature
Prior art date
Application number
PCT/CN2021/091707
Other languages
English (en)
French (fr)
Inventor
郑苏欣
谢成英
郑明月
陆晓杰
乔刚
Original Assignee
苏州阿尔脉生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州阿尔脉生物科技有限公司 filed Critical 苏州阿尔脉生物科技有限公司
Priority to EP21804225.7A priority Critical patent/EP4140997A4/en
Priority to JP2022569623A priority patent/JP7451765B2/ja
Priority to US17/924,720 priority patent/US20230219961A1/en
Publication of WO2021227906A1 publication Critical patent/WO2021227906A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • the invention belongs to the technical field of pyridine acetamide derivatives, and specifically relates to a pyridine acetamide derivative as a CDK inhibitor, a preparation method and application thereof.
  • CDKs Cell cycle-dependent protein kinases
  • CDKs are a class of serine/threonine kinases that play a key role in cell cycle regulation and cell transcription. They are increasingly used as important targets for the treatment of cancer and other diseases. s concern.
  • the CDKs family has 13 different subtypes with similar structures, which can be activated by about 10 cyclins to perform different biological functions. According to different mechanisms of action, it is generally divided into cell cycle CDK (CDK1-6) and transcriptional CDK (CDK7-9).
  • CDK9 is mainly involved in the process of transcription regulation.
  • the heterodimer composed of CDK9 and cyclin (T1, T2a, T2b, K) participates in the formation of positive transcription elongation factor (P-TEFb), which plays a key role in the process of transcription regulation.
  • P-TEFb positive transcription elongation factor
  • CDK9 has a classic protein kinase fold, consisting of C-terminal and N-terminal kinase domains and a small C-terminal extension.
  • P-TEFb positive transcription elongation factor
  • CDK9 regulates RNA transcription of short-lived anti-apoptotic proteins.
  • CDK9 regulates the expression of anti-apoptotic proteins by phosphorylating RNApol II.
  • the transcription catalyzed by RNApol II is a multi-step process.
  • the C-terminal domain of RNApol II large subunit contains the tandem heptapeptide repeat sequence.
  • the phosphorylation of Ser and Thr plays an important role in the transcription process.
  • CDK9 in the P-TEFb complex phosphorylates Ser at 2 of RNApol II CTD, it also phosphorylates sensitive inducible factor DSIF and negative elongation factor NELF. Phosphorylation causes NELF to leave and at the same time converts DSIF into a positive transcription factor. Then RNApol II enters the transcription elongation mode, and the transcription elongation process starts 1 .
  • CDK7, cyclin H and Mat1 form the catalytic center of CDK-activatig kinase (CAK), which phosphorylates CDK1, 2, 4 and 6 to maintain the cell cycle process.
  • CAK is a component of the transcription factor TFIIH in RNA polymerase II (RNAPII), which can phosphorylate the Rbp1 subunit of the C-terminal (CTD) of RNAPII, and the phosphorylation of CTD regulates the transcription of RNAPII.
  • RNAPII RNA polymerase II
  • CDK7 can activate CDK9 through the phosphorylation of T-loop, thereby further regulating transcription 2 .
  • CDK9 Inhibition of CDK9 will lead to the down-regulation of anti-apoptotic proteins Mcl-1, XIAP, etc., so that these anti-apoptotic proteins lose their ability to maintain the stability of tumor cells, thereby inducing tumor cell apoptosis.
  • CDK9 is also involved in the regulation of many cell functions. Selective inhibition of CDK9 can also be used as a potential treatment strategy for tumor invasion and metastasis. Recently reported through CDK9 inhibitors inhibiting transcription and post-transcriptional modification thus lowered MYC protein, it is the role of inhibition of MYC 3 driven tumors.
  • inhibiting CDK9 can increase the number of CD45 + cells in the tumor environment, increase the proportion of CD3 + T cells and activate dendritic cells.
  • CDK9 inhibitors can enhance the immune response of tumor immune checkpoint inhibitors (checkpoint blockage) 4 .
  • CDK is an important target for the treatment of tumors and other diseases.
  • many CDK inhibitors have entered the clinic, and selective CDK4/6 inhibitors have been marketed, which brings confidence and hope for the development of selective CDK inhibitors.
  • CDK9 as a novel and huge potential anti-tumor drug target, has received more and more attention.
  • a number of selective CDK9 inhibitors have entered the clinic (Fadraciclib, Zotitraciclib, KB-130742 and AZD-4573, etc.), with CDK9 as the target Anti-tumor drug targets have broad application prospects.
  • CDK7 or CDK9 have high selectivity to CDK7 or CDK9 (WO2017001354, WO2018192273, WO2019154177, etc.).
  • CDK7 or CDK9 have high selectivity to CDK7 or CDK9 (WO2017001354, WO2018192273, WO2019154177, etc.).
  • the purpose of the present invention is to provide a pyridine acetamide derivative, a pharmaceutically acceptable salt, a tautomer or a stereoisomer thereof, so as to screen out effective Compounds that have excellent properties in terms of sex, safety, selectivity, etc., are used as CDK family including but not limited to CDK9 or CDK7 inhibitors.
  • Another object of the present invention is to provide a method for preparing the derivative, its pharmaceutically acceptable salt, its tautomer or its stereoisomer.
  • the present invention provides a pyridine acetamide derivative, a pharmaceutically acceptable salt thereof, a tautomer or a stereoisomer thereof, and the structure of the pyridine acetamide derivative is as follows: I) shows:
  • R 1 is selected from hydrogen, halogen, cyano, substituted or unsubstituted C 1 -C 3 alkyl or substituted or unsubstituted C 1 -C 3 alkoxy, wherein "substituted” here means optionally ⁇ is further substituted with 1-3 halogens;
  • R 21 and R 22 are each independently selected from hydrogen, halogen, hydroxyl, cyano, amino, substituted or unsubstituted C 1 -C 3 alkyl, and substituted or unsubstituted C 1 -C 3 alkoxy, wherein, Substitution here refers to optionally substituted by 1-3 halogens, hydroxyl groups, cyano groups or amino groups;
  • AR 1 is selected from phenyl, 5-6 membered heteroaryl, 8-10 membered fused aryl and 8-10 membered fused heteroaryl, and among them, phenyl, 5-6 membered heteroaryl, 8 -10 membered fused aryl, and 8-10 membered fused heteroaryl is optionally substituted with one or more further substituted by R a;
  • R a is independently selected from C 1 -C 3 alkyl, hydroxy, halo, cyano, amino, C 1 -C 3 alkoxy, C 3 -C 6 cycloalkyl, C 3 -C 6 heterocyclyl, Phenyl, 5-6 membered heteroaryl, S(O)R b1 , S(O) 2 R b1 , S(O)NH 2 , S(O)NHR b1 , S(O)NR b1 R b2 , S(O) 2 NH 2 , S(O) 2 NHR b1 , S(O) 2 NR b1 R b2 , NHS(O)R b1 , NR b1 S(O)R b2 , NHS(O) 2 R b1 , NR b1 S(O) 2 R b2 , C(O)R b1 , C(O)OR b1 , OC(O)R b1 , N
  • R b1 and R b2 are each independently selected from alkyl, 3-6 C1-C 3-membered cycloalkyl or heterocyclyl, wherein alkyl, cycloalkyl and heterocyclyl optionally further substituted by 1-3 Substituted by a substituent selected from alkyl, hydroxy, halogen, cyano, amino or alkoxy, or R b1 and R b2 together with the N atom to which they are attached form a 3-7 membered heterocyclic group;
  • R 3 is selected from:
  • Z is N or CR c ;
  • R c is independently selected from hydrogen, halogen, cyano, C(O)NH 2 , C(O)NHR b , C(O)NR b1 R b2 , C(O)R b or C1-C 3 alkyl , Wherein the alkyl group is optionally further substituted with 1-3 substituents selected from alkyl, hydroxy, halogen, cyano, amino or alkoxy;
  • X and Y together with the atoms to which they are attached form a 5-7 membered heterocyclic group or cycloalkyl group, wherein the heterocyclic group includes 1-2 heteroatoms selected from N, O, S; the 5-7 membered heterocyclic ring
  • the group or cycloalkyl group is saturated or partially saturated and the ring carbon or ring S atom is optionally further substituted with 1-3 Rd ;
  • the structure of the pyridine acetamide derivatives is as shown in formula (II):
  • R 1 , R 21 , R 22 , AR 1 and R c have the same limited ranges as the above general formula (I).
  • R 1 , R 21 , R 22 , AR 1 and R c have the same limited ranges as the above general formula (I).
  • R 1 , R 21 , R 22 and AR 1 have the same limited range as the above general formula (I).
  • R 1 , R 21 , R 22 and AR 1 have the same limited range as the above general formula (I).
  • the pyridine acetamide derivative is selected from any one of the following structures:
  • the present invention provides a method for preparing the pyridine acetamide derivatives, pharmaceutically acceptable salts thereof, tautomers or stereoisomers thereof as described in the first aspect, which are selected from One of the following three options:
  • the compound of general formula (I-2) is under basic conditions in the presence of a metal catalyst to obtain a compound of general formula (I-3);
  • the compound of general formula (I-5) is subjected to acidic conditions, and the Boc protecting group is removed to obtain the compound of general formula (I-A);
  • the compound of general formula (I-A) and the compound of general formula (I-B) undergo condensation reaction under basic conditions to obtain the compound of general formula (I).
  • R 1 , AR 1 , R 21 , R 22 and R 3 have the same limited ranges as the above general formula (I).
  • a compound of general formula (I-4) is obtained under basic conditions in the presence of a metal catalyst to obtain a compound of general formula (I-Bb);
  • the compound of general formula (I-1) and the compound of general formula (I-B) undergo condensation reaction under basic conditions to obtain the compound of general formula (I-Aa);
  • the compound of general formula (I-Aa) and the compound of general formula (I-Bb) undergo Suzuki reaction under basic conditions in the presence of a metal catalyst and ligand to obtain a compound of general formula (I) .
  • X is halogen, preferably bromine;
  • W is R 1 , AR 1 , R 21 , R 22 and R 3 have the same defined ranges as the above general formula (I).
  • the compound of general formula (IB) and ammonium chloride undergo a condensation reaction under alkaline conditions to obtain the compound of general formula (I-Bbb); or, the compound of general formula (I-6) under alkaline conditions
  • the compound of general formula (I-Bbb) is obtained by oxidation;
  • the compound of general formula (I-7) and the compound of general formula (I-Bb) undergo Suzuki reaction under basic conditions in the presence of a catalyst to obtain the compound of general formula (I-Aaa);
  • the compound of general formula (I-Aaa) and the compound of general formula (I-Bbb) undergo condensation reaction under basic conditions to obtain the compound of general formula (I).
  • X is halogen, preferably chlorine;
  • R 1 , AR 1 , R 21 , R 22 and R 3 have the same defined range as the above general formula (I).
  • the reagents that provide alkaline conditions are selected from organic bases or inorganic bases
  • the organic bases include, but are not limited to, triethylamine, N,N-diisopropylethylamine, and n-butyl lithium , Lithium diisopropylamide, lithium bistrimethylsilylamide, potassium acetate, sodium acetate, sodium tert-butoxide, sodium methoxide and potassium tert-butoxide, the inorganic bases
  • the organic bases include, but are not limited to, triethylamine, N,N-diisopropylethylamine, and n-butyl lithium , Lithium diisopropylamide, lithium bistrimethylsilylamide, potassium acetate, sodium acetate, sodium tert-butoxide, sodium methoxide and potassium tert-butoxide, the inorganic bases
  • Reagents that provide acidic conditions include, but are not limited to, one or more of hydrogen chloride, 1,4-dioxane solution of hydrogen chloride, trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, methanesulfonic acid, nitric acid, and phosphoric acid;
  • Metal catalysts include but are not limited to palladium/carbon, Raney nickel, tetra-triphenylphosphine palladium, palladium dichloride, palladium acetate, [1,1'-bis(diphenylphosphino)ferrocene]dichloride Palladium (Pd(dppf)Cl 2 ), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride dichloromethane complex, bis(triphenylphosphine) palladium dichloride ( One or more of Pd(PPh 3 )Cl 2 ) and tris(dibenzylideneacetone)dipalladium (Pd 2 (dba) 3 );
  • Ligands include but are not limited to 2-biscyclohexylphosphine-2,6'-dimethoxybiphenyl (SPhos), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (XantPhos) , 2-Dicyclohexylphosphorus-2,4,6-triisopropylbiphenyl (XPhos), 2-Dicyclohexylphosphino-2'-(N,N-dimethylamine)-biphenyl (DavePhos) , 1,1'-bis(diphenylphosphine)ferrocene (Dppf) and 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (BINAP) one or more, preferably 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (XantPhos);
  • Condensing agents include, but are not limited to, dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI), 2-(7-benzotriazole oxide)-N,N,N',N' -Tetramethylurea hexafluorophosphate (HATU), 2-(1H-benzotrisazo L-1-yl)-1,1,3,3-tetramethylurea tetrafluoroborate (TBTU) , One or more of 1-hydroxybenzotriazole (HOBt) and 1-propyl phosphoric anhydride (T3P).
  • DCC dicyclohexylcarbodiimide
  • DIC 1-(3-dimethylaminopropyl)-3-e
  • the above reaction is preferably carried out in a solvent.
  • the solvents used include but are not limited to: N,N-dimethylformamide, dimethylsulfoxide, 1,4-dioxane, water, tetrahydrofuran, dichloromethane, 1, 2-Dichloroethane, acetic acid, methanol, ethanol, toluene, petroleum ether, ethyl acetate, n-hexane, acetone, ether, diethylene glycol and mixtures thereof.
  • the present invention provides a pharmaceutical composition, which includes the pyridine acetamide derivatives, stereoisomers, tautomers, and pharmaceutically acceptable salts as described above;
  • the pharmaceutical composition further includes a pharmaceutically acceptable carrier and/or excipient.
  • the present invention provides a pyridine acetamide derivative, stereoisomer, tautomer, pharmaceutically acceptable salt, or pharmaceutical composition as described in the third aspect as described in the first aspect.
  • the cancer preferably blood cancer
  • the cancer includes acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, and follicular lymphoma
  • solid tumors including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer and lung cancer.
  • the present invention also provides a method for treating cancer with pyridine acetamide derivatives used as CDK inhibitors, which is carried out by administering an effective amount of the compound to a subject suffering from cancer.
  • the compounds of the present invention can be further administered in combination with a therapeutically effective amount of one or more agents for the treatment of cancer.
  • agents include, for example, radiation, alkylating agents, angiogenesis inhibitors, anti-mitotic agents, and anti-proliferative agents.
  • Agent Aurora kinase inhibitor, cell death activator (for example, inhibitor of Bcl-2, BclxL, Bcl-w, Bfl-1, or Mcl-1), activator of death receptor pathway, Bcr-Abl kinase inhibitor Agents, BET (bromine domain protein) inhibitors, Ras signaling pathway inhibitors (e.g.
  • inhibitors of MEK, Raf or Ras antibodies, BiTE (bispecific T cell adaptor) antibodies, antibody-drug conjugates, biological Response modifier, cyclin-dependent kinase inhibitor, cell cycle inhibitor, cyclooxygenase-2 inhibitor, DVD (dual variable domain antibody), leukemia virus oncogene homolog (ErbB2) receptor inhibitor , Growth factor inhibitors, heat shock protein (HSP)-90 inhibitors, histone deacetylase (HDAC) inhibitors, hormone therapy, immunologic drugs, inhibitors of apoptosis proteins (IAP), kinase inhibitors, Tumor kinesin inhibitor, Jak2 inhibitor, mammalian target of rapamycin inhibitor, microRNA, mitogen activated extracellular signal-regulated kinase inhibitor, poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitors, platinum chemotherapeutics, polo-like kinase (Plk) inhibitors, phosphoinositide
  • the term "effective amount” means an amount of a compound or composition sufficient to significantly and positively alter the symptoms and/or conditions to be treated (eg, provide a positive clinical response).
  • the effective amount of the active ingredient used in a pharmaceutical composition will vary with the specific condition being treated, the severity of the condition, the duration of the treatment, the nature of the concurrent treatment, and the specific use of the one or more The active ingredients, one or more pharmaceutically acceptable excipients/carriers used, and similar factors within the knowledge and professional skills of the attending doctor vary.
  • an effective amount of the compound of formula (I) for use in cancer treatment is an amount sufficient to symptomatically alleviate the symptoms of cancer in humans, so as to slow the progression of cancer, or reduce symptoms in patients suffering from cancer. The risk of deterioration.
  • Alkyl refers to a saturated aliphatic hydrocarbon group, including 1-20 carbon atoms, or 1-10 carbon atoms, or 1-6 carbon atoms, or 1-4 carbon atoms, or 1-3 carbon atoms , Or a saturated linear or branched monovalent hydrocarbon group with 1-2 carbon atoms, wherein the alkyl group can be independently optionally substituted with one or more substituents described in the present invention.
  • alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1 ,1-Dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, N-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2 -Dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-di Methyl butyl and so on.
  • Alkyl groups can be optionally substituted or unsubstituted.
  • Alkenyl refers to a linear or branched monovalent hydrocarbon group of 2-12 carbon atoms, or 2-8 carbon atoms, or 2-6 carbon atoms, or 2-4 carbon atoms, in which at least one CC is sp 2 double bond, wherein the alkenyl group can be independently and optionally substituted by one or more substituents described in the present invention, specific examples of which include, but are not limited to, vinyl, allyl and alkene Butyl and so on. Alkenyl groups can be optionally substituted or unsubstituted.
  • Cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent.
  • the cycloalkyl ring includes 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, and more preferably 3 to 6 Carbon atoms.
  • Non-limiting examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl , Cycloheptatrienyl, cyclooctyl, etc.; polycyclic cycloalkyls include spiro, fused, and bridged cycloalkyls. Cycloalkyl groups can be optionally substituted or unsubstituted.
  • “Spirocycloalkyl” refers to a polycyclic group with 5 to 18 members, two or more cyclic structures, and the single rings share one carbon atom (called a spiro atom) with each other.
  • the ring contains one or more A double bond, but none of the rings have a fully conjugated ⁇ -electron aromatic system. It is preferably 6 to 14 yuan, more preferably 7 to 10 yuan.
  • the spirocycloalkyls are classified into monospiro, dispiro or polyspirocycloalkyls, preferably monospiro and dispirocycloalkyls, preferably 4-membered/5-membered, 4-membered Yuan/6 Yuan, 5 Yuan/5 Yuan or 5 Yuan/6 Yuan.
  • spirocycloalkyl include, but are not limited to:
  • “Fused cycloalkyl” refers to a 5- to 18-membered, all-carbon polycyclic group containing two or more cyclic structures sharing a pair of carbon atoms with each other.
  • One or more rings may contain one or more double bonds, However, none of the rings has a fully conjugated ⁇ -electron aromatic system, preferably 6 to 12 members, more preferably 7 to 10 members.
  • it can be classified into bicyclic, tricyclic, tetracyclic or polycyclic condensed cycloalkyls, preferably bicyclic or tricyclic, and more preferably 5-membered/5-membered or 5-membered/6-membered bicyclic alkyl.
  • Non-limiting examples of "fused cycloalkyl” include, but are not limited to:
  • Bridged cycloalkyl refers to a 5- to 18-membered, all-carbon polycyclic group containing two or more cyclic structures that share two carbon atoms that are not directly connected to each other.
  • One or more rings may contain one or An aromatic system with multiple double bonds, but none of the rings having fully conjugated ⁇ electrons, is preferably 6 to 12 members, and more preferably 7 to 10 members.
  • it can be classified into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyls, preferably bicyclic, tricyclic or tetracyclic, and more preferably bicyclic or tricyclic.
  • bridged cycloalkyl include, but are not limited to:
  • the cycloalkyl ring may be fused to an aryl, heteroaryl or heterocyclyl ring, wherein the ring connected to the parent structure is a cycloalkyl group, non-limiting examples include indanyl, tetrahydronaphthalene Group, benzocycloheptanyl, etc.
  • Heterocyclic “heterocyclic” or “heterocyclic” are used interchangeably in this application, and are used interchangeably in this application, and all refer to a saturated or partially unsaturated monocyclic ring containing 3-12 ring atoms ,
  • a bicyclic or tricyclic non-aromatic heterocyclic group in which at least one of the ring atoms is a heteroatom, such as oxygen, nitrogen, and sulfur atoms. It preferably has a 5- to 7-membered monocyclic ring or a 7- to 10-membered bi- or tricyclic ring, which may contain 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulfur.
  • heterocyclyl examples include, but are not limited to, morpholinyl, oxetanyl, thiomorpholinyl, tetrahydropyranyl, 1,1-dioxo-thiomorpholinyl, piperidine Group, 2-oxo-piperidinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl and Piperazinyl.
  • the heterocyclic ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclic group.
  • the heterocyclic group may be optionally substituted or unsubstituted.
  • “Spiroheterocyclic group” refers to a polycyclic group with 5 to 18 members, two or more cyclic structures, and the single rings share one atom with each other.
  • the spiro heterocyclic group is classified into a single spiro heterocyclic group, a dispiro heterocyclic group or a polyspiro heterocyclic group, preferably a single spiro heterocyclic group and a dispiro heterocyclic group. More preferably, it is a 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered monospiro heterocyclic group.
  • spiroheterocyclyl include, but are not limited to:
  • “Fused heterocyclic group” refers to an all-carbon polycyclic group containing two or more ring structures that share a pair of atoms with each other.
  • bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups preferably bicyclic or tricyclic, more preferably 5-membered/5-membered or 5-membered/6-membered bicyclic fused heterocyclic group.
  • fused heterocyclyl include, but are not limited to:
  • “Bridged heterocyclic group” refers to a 5- to 18-membered polycyclic group containing two or more cyclic structures that share two atoms that are not directly connected to each other.
  • bridged heterocyclyl include, but are not limited to:
  • Aryl refers to a carbocyclic aromatic system containing one or two rings, wherein the rings can be joined together in a fused manner.
  • aryl includes aromatic groups such as phenyl, naphthyl, and tetrahydronaphthyl.
  • the aryl group is a C 6 -C 10 aryl group, more preferably the aryl group is a phenyl group and a naphthyl group, and most preferably a phenyl group.
  • Aryl groups can be substituted or unsubstituted.
  • the "aryl” can be condensed with a heteroaryl, heterocyclic or cycloalkyl group, wherein the aryl ring is connected to the parent structure. Non-limiting examples include but are not limited to:
  • Heteroaryl refers to an aromatic 5- to 6-membered monocyclic ring or 9 to 10-membered bicyclic ring, which may contain 1 to 4 atoms selected from nitrogen, oxygen, and/or sulfur.
  • heteroaryl include, but are not limited to, furyl, pyridyl, 2-oxo-1,2-dihydropyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl , Oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzobis Oxolol, benzimidazolyl, indolyl, isoindolyl, 1,3-dioxo-isoindolyl, quin
  • Heteroaryl groups can be optionally substituted or unsubstituted.
  • the heteroaryl ring may be fused to an aryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring.
  • Non-limiting examples include but are not limited to:
  • Alkoxy refers to a (alkyl-O-) group. Among them, the alkyl group is defined in this article. C 1 -C 6 alkoxy groups are preferred. Examples thereof include, but are not limited to: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy and the like.
  • Haloalkyl refers to an alkyl group having one or more halogen substituents, wherein the alkyl group has the meaning as described in the present invention.
  • haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, perfluoroethyl, 1,1-dichloroethyl, 1,2-dichloropropyl, and the like.
  • Halogen refers to fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine and bromine.
  • Amino refers to -NH 2 .
  • Cyano refers to -CN.
  • Niro refers to -NO 2 .
  • Benzyl refers to -CH 2 -phenyl.
  • Carboxy refers to -C(O)OH.
  • Alcohol refers to -C(O)CH 3 or Ac.
  • Carboxylic acid ester group refers to -C(O)O(alkyl) or (cycloalkyl), wherein the definitions of alkyl and cycloalkyl are as described above.
  • AR 1 is optionally substituted with one to more R c
  • R c includes the description that the AR 1 group may be substituted with one to more R c or not substituted with R c.
  • Substituted refers to one or more hydrogen atoms in the group, preferably up to 5, more preferably 1-3 hydrogen atoms independently of each other replaced by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without too much effort. For example, an amino group or a hydroxyl group having free hydrogen may be unstable when combined with a carbon atom having an unsaturated (e.g., olefinic) bond.
  • the compounds of the present invention may contain asymmetric centers or chiral centers, so there are different stereoisomers. All stereoisomeric forms of the compounds of the present invention, including but not limited to, diastereomers, enantiomers, atropisomers, and their mixtures, such as racemic mixtures, constitute the present invention Part.
  • Diastereomers can be separated into individual diastereomers by methods such as chromatography, crystallization, distillation or sublimation based on their physical and chemical differences.
  • Enantiomers can be separated to convert a chiral isomeric mixture into a diastereomeric mixture by reaction with a suitable optically active compound (for example, a chiral auxiliary, such as a chiral alcohol or Mosher's acid chloride) , Separate diastereomers, and convert individual diastereomers into corresponding pure enantiomers.
  • a suitable optically active compound for example, a chiral auxiliary, such as a chiral alcohol or Mosher's acid chloride
  • the intermediates and compounds of the present invention may also exist in different tautomeric forms, and all such forms are included in the scope of the present invention.
  • optically active compounds that is, they have the ability to rotate the plane of plane-polarized light.
  • the prefixes D, L or R, S are used to indicate the absolute configuration of the chiral center of the molecule.
  • the prefixes d, l or (+), (-) are used to name the symbols of the plane-polarized light rotation of the compound, (-) or l means that the compound is levorotatory, and the prefix (+) or d means that the compound is dextrorotatory.
  • the atoms or atomic groups of these stereoisomers are connected to each other in the same order, but their stereostructures are different.
  • a specific stereoisomer may be an enantiomer, and a mixture of isomers is usually called an enantiomeric mixture.
  • a 50:50 mixture of enantiomers is called a racemic mixture or a racemate, which may result in no stereoselectivity or stereospecificity in the chemical reaction process.
  • the terms “racemic mixture” and “racemate” refer to an equimolar mixture of two enantiomers, lacking optical activity.
  • Tautomers or “tautomeric forms” mean that isomers of different energy structures can be converted into each other through a low energy barrier.
  • proton tautomers ie, tautomers of proton transfer
  • Atomic (valence) tautomers include the interconversion of recombined bond electrons.
  • the structural formula described in the present invention includes all isomeric forms (such as enantiomers, diastereomers, and geometric isomers): for example, R and S configurations containing asymmetric centers, The (Z) and (E) isomers of the double bond, and the (Z) and (E) conformational isomers. Therefore, a single stereochemical isomer of the compound of the present invention or a mixture of its enantiomers, diastereomers, or geometric isomers all belong to the scope of the present invention.
  • “Pharmaceutically acceptable salt” refers to the salt of the compound of the present invention, which is safe and effective when used in humans or animals.
  • the salt of the compound can be obtained by using a sufficient amount of base or acid in a pure solution or a suitable inert solution to obtain the corresponding addition salt.
  • Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic ammonia or magnesium salts, etc.
  • Pharmaceutically acceptable acid addition salts include inorganic acid salts and organic acid salts.
  • the inorganic and organic acids include Hydrochloric acid, hydrobromic acid, carbonic acid, hydrogen carbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, monohydrogen sulfate, acetic acid, maleic acid, malonic acid, succinic acid, ricebutenedioic acid, Phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid and methanesulfonic acid, etc. (see Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science 66:1-19 (1977)).
  • the pyridine acetamide derivatives used as CDK inhibitors provided by the present invention have the following beneficial effects:
  • the present invention provides a CDK inhibitor with a new structure.
  • the test results show that the pyridine acetamide derivatives exhibit excellent CDK7/CDK9 enzyme inhibitory activity and can be used to prepare and treat cancer, especially blood cancer, including acute myeloid cells.
  • Figure 1 shows the SDS-PAGE electrophoresis detection diagram of the inhibitory effects of compounds 2-2, 3, 11-2, 13-1, 13-2 and AZD4573 on the phosphorylation of RNA pol II Ser2/5 of Mv4-11 cells.
  • the 1 H NMR spectrum is measured by a Bruker instrument (400 MHz), and the chemical shift is expressed in ppm. Use tetramethylsilane internal standard (0.00ppm).
  • the mass spectrum is measured by an LC/MS instrument, and the ionization method is ESI.
  • High performance liquid chromatograph model Agilent 1260, Thermo Fisher U3000; Column model: Waters xbrige C18 (4.6*150mm, 3.5 ⁇ m); mobile phase: A: ACN, B: Water (0.1% H 3 PO 4 ); Flow rate: 1.0mL/min; Gradient: 5%A for 1min, increase to 20%A within 4min, increase to 80%A within 8min, 80%A for 2min, back to 5%A within 0.1min; Wavelength: 220nm; Column oven: 35°C.
  • the thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, the size of the silica gel plate used in thin layer chromatography (TLC) is 0.2mm-0.3mm, and the size of the thin layer chromatography separation and purification product is 0.4mm. -0.5mm.
  • HATU 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethylurea hexafluorophosphate
  • the hydrogen atmosphere means that the reaction flask is connected to a hydrogen balloon with a volume of about 1L.
  • reaction temperature is room temperature, which is 20°C-30°C.
  • the monitoring of the reaction progress in the examples adopts thin-layer chromatography (TLC).
  • the developing reagent used in the reaction, the eluent system of column chromatography used in the purification of the compound or the developing reagent system of thin-layer chromatography include: A: Petroleum ether and ethyl acetate system; B: dichloromethane and methanol system; C: n-hexane: ethyl acetate; the volume ratio of the solvent varies according to the polarity of the compound, and a small amount of acidic or alkaline reagents can also be added Make adjustments such as acetic acid or triethylamine.
  • the first step is methyl hydroxytrimethyl acetate IN-1b
  • reaction solution was poured into water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated and purified by silica gel column chromatography to obtain the title compound IN-1c (121.0g, crude product) as a pale yellow transparent liquid , Used directly in the next step.
  • reaction solution was slowly poured into water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound IN-1g (18.1g, two Step yield 55%).
  • the seventh step 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole IN-1h
  • the ninth step 5,5-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)-5,6-dihydro- 4H-pyrrolo[1,2-b]pyrazole IN-1
  • reaction solution was cooled to room temperature, water was added, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound IN-1 (2.4g, yield) as a pale yellow liquid. Rate 36%).
  • the first step (4-bromo-5-chloropyridin-2-yl) di-tert-butyl iminodicarbonate IN-2b
  • 4-bromo-5-chloropyridine-2-amino IN-2a (3.0g, 14.5mmol) was dispersed in a mixed solvent (100mL) of tert-butanol/acetone (1:1), and triethylamine (6.2g, 61.3mmol), di-tert-butyl dicarbonate (12.7g, 58.2mmol) and 4-dimethylaminopyridine (catalytic amount), stirred at room temperature for 3 hours, TLC showed that the reaction of the raw materials was complete.
  • reaction solution was concentrated to remove the organic solvent, diluted with water, extracted with ethyl acetate, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain the title compound IN-2b (7.5g, crude product) as a white solid ), directly used in the next step.
  • reaction solution was cooled to room temperature, filtered, the filter cake was washed with ethyl acetate, the filtrate was diluted with water, extracted with ethyl acetate, the organic phases were combined, washed with water, washed with saturated brine, dried with anhydrous sodium sulfate, and concentrated to obtain the title compound IN-2c as a brown oil (2.5g, crude product) used directly in the next step.
  • the reaction solution was cooled to room temperature, filtered, the filter cake was washed several times with ethyl acetate, the filtrate was diluted with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude product was purified by silica gel column chromatography to obtain white Solid title compound IN-2d (398 mg, yield 86%).
  • the third step 4-(4-bromo-2-cyano-1H-pyrrol-1-yl)-3,3-dimethylbutyrate methyl ester IN-3d
  • the fourth step 4-(4-bromo-2-cyano-1H-pyrrol-1-yl)-3,3-dimethylbutanoic acid IN-3e
  • reaction solution was concentrated to remove the organic solvent, diluted with water, extracted with ethyl acetate, the organic phase was discarded, the aqueous phase was adjusted to acidity with dilute hydrochloric acid (1N), extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, and anhydrous sodium sulfate After drying and concentration, the title compound IN-3e (1.4 g, crude product) was obtained as a yellow oil, which was used directly in the next step.
  • the fifth step 4-(4-bromo-2-cyano-1H-pyrrol-1-yl)-3,3-dimethylbutyryl chloride IN-3f
  • reaction solution was poured into ice water to quench, added hydrochloric acid (1N) to adjust the pH to acidity, extracted with dichloromethane, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain a white solid title Compound IN-3g (900mg, three-step yield 62%).
  • the ninth step (5-chloro-4-(5-cyano-2,2-dimethyl-2,3-dihydro-1H-pyrrolazine-7-yl)pyridin-2-yl)iminodicarbonic acid Di-tert-butyl ester IN-3j
  • reaction solution was cooled to room temperature, filtered, the filter cake was washed with ethyl acetate, the filtrate was diluted with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain a white solid title Compound IN-3j (300 mg, 26% yield in three steps).
  • reaction solution was added with water, extracted with dichloromethane, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain 1 g (105 mg, crude product) of the title compound as a pale yellow solid, which was used directly in the next step.
  • reaction solution was added with water, extracted with dichloromethane, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the crude product was purified by Prep-TLC to obtain the title compound 1 (29 mg, 6-step yield 1%) as a white solid.
  • reaction solution was quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated and purified by silica gel column chromatography to obtain the title compound 2a as a yellow liquid (1.6g, yield 30%) .
  • the solid title compound 2d (910 mg, crude product) was used directly in the next step.
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 2e (200mg, collected in two steps) as a white solid Rate 43%).
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 2f (90mg, yield) as a white solid 31%).
  • reaction solution was quenched with water, extracted with ethyl acetate, combined the organic phases, washed with water, washed with saturated brine, dried with anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 3f (210mg, 6-step yield 28.8). %).
  • the seventh step 3- (2-((5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl) (Pyridin-2-yl)amino)-2-oxoethyl)-N-methylbenzamide 3
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate, combined the organic phases, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated and purified by Prep-TLC to obtain the title compound 3 as a white solid (32mg, yield) 29%).
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 4a (537 mg, yield 68) as a white solid %).
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated and purified by Prep-TLC to obtain the title compound 4 (38 mg, yield 33%) as a white solid ).
  • Methyl pyridine-4-acetate 5a (2.0 g, 13.23 mmol) was dissolved in tetrahydrofuran/water (10 mL/5 mL), sodium hydroxide (1.32 g, 33.01 mmol) was added, and the mixture was stirred at room temperature for 2 hours. TLC showed that the reaction was complete.
  • the title compound 5b (1.40 g, crude product) was obtained as a white solid, which was used directly in the next step.
  • reaction solution was cooled to room temperature, quenched with water, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 5 (33 mg, yield 28.2%) as a white solid.
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was used to obtain the title compound 6 as a white solid (33 mg, three-step yield: 16 %).
  • 2-Bromo-6-methylpyridine 7a (5.0g, 29.1mmol) was dissolved in anhydrous tetrahydrofuran (30mL), under the protection of nitrogen, the temperature was reduced to -50°C, and lithium diisopropylamide (39mL, 78.0 mmol, 2M tetrahydrofuran solution), methyl chloroformate 7b (3.2g, 33.9mmol), after the dropwise addition, stirred at -50°C for 15 minutes, TLC showed that the reaction was complete.
  • reaction solution was poured into water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated and purified by silica gel column chromatography to obtain the title compound 7c (1.2g, yield 15%) as a pale yellow solid. .
  • reaction solution was cooled to room temperature, poured into water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried with anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 7d (710mg, yield). Rate 84%).
  • reaction solution was cooled to room temperature, poured into water, saturated sodium bicarbonate solution was adjusted to pH 8-9, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain the title compound 7f( 600mg, crude product), used directly in the next step.
  • reaction solution was cooled to room temperature, poured into water, extracted with ethyl acetate, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain the title compound 7 (70 mg, yield 39%) as a white solid.
  • reaction solution was cooled to room temperature, water was added, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated and purified by silica gel column chromatography to obtain the title compound 8a (450mg, two-step yield). 33%).
  • reaction solution was added with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 8c (180 mg, yield 18%) as a pale yellow solid.
  • reaction solution was cooled to room temperature, slowly poured into water, extracted with ethyl acetate, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated and purified by silica gel column chromatography, and purified by Prep-TLC to obtain the title compound as a white solid 8 (22mg, yield 11%).
  • the first step is methyl 2-(3-((tert-butoxycarbonyl)amino)phenyl)acetate 9a
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 9a (625mg, Yield 54%).
  • reaction solution was quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 9c (830 mg, two-step yield 80%) as a white solid ).
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 9d (78mg, yield) as a white solid 35%).
  • reaction solution was quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 10a (200 mg, yield 71%) as a white solid.
  • reaction solution was quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 11a (600 mg, yield 55%) as a yellow oily liquid.
  • reaction solution was quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 11c as a white solid (600 mg, two-step yield 53%) .
  • the first step 3-(2,5-dichloropyridin-4-yl)-5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 12b
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain the title compound 12b (108 mg, yield) as a pale yellow solid 52%).
  • 2-Methoxy-5-methylpyridine 12c (2.0g, 16.24mmol) was dissolved in carbon tetrachloride (40mL), and N-bromosuccinimide (3.18g, 17.87mmol) and Azobisisobutyronitrile (0.27 g, 1.64 mmol) was heated to 70° C. and reacted for 2 hours. TLC showed that the reaction was complete. The reaction solution was concentrated, slurried with ethyl acetate, filtered, and the filter cake was washed and dried to obtain the title compound 12d (2.9 g, yield 88%) as a yellow liquid.
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by Prep-TLC to obtain the title compound 12 as a white solid (13 mg, yield 16%) .
  • the first step is methyl 2-(6-bromopyridin-2-yl)propionate 13a
  • reaction solution was quenched with dilute hydrochloric acid (1N), extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated and purified by silica gel column chromatography to obtain the title compound 13a (3.9g, yield) as a white solid Rate 68%).
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 13d (640mg, yield 52) as a white solid %).
  • the first step is methyl 2-(3-((tert-butoxycarbonyl)amino)phenyl)propionate 14a
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 14a as a brown liquid (1.6g, yield) 80%).
  • the third step (3-(1-((5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl )Pyridin-2-yl)amino)-1-oxopropan-2-yl)phenyl)tert-butyl carbamate 14c
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 14c (280mg, yield 58) as a white solid %).
  • 2-Bromo-4-methylpyridine 15a (10.0g, 58.13mmol) was dissolved in anhydrous tetrahydrofuran (150mL), cooled to -70°C, and slowly added lithium diisopropylamide (87.2mL, 174.4mmol, 2M tetrahydrofuran solution) ), react at -70°C for 1 hour, slowly add methyl chloroformate (7.14 g, 75.56 mmol) dropwise, slowly warm to room temperature after the addition, and react for 1 hour. TLC shows that the reaction is complete.
  • reaction solution was quenched by adding saturated aqueous ammonium chloride solution, extracted with ethyl acetate, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 15b (9.5g, yield) as a yellow liquid. The rate is 71%).
  • reaction solution was quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated and purified by silica gel column chromatography to obtain the title compound 15c (4.4g, yield 69%) as a yellow oily liquid .
  • the solid title compound 15d (365 mg, crude product) was used directly in the next step.
  • reaction solution was quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was separated and purified to obtain the title compound 15e (610 mg, yield 89%) as a white solid.
  • 2-Methoxy-4-methylpyridine 16a (2.0g, 16.2mmol) was dissolved in anhydrous tetrahydrofuran (20mL). Under nitrogen protection, the temperature was lowered to -60°C, and lithium diisopropylamide (20.4 mL, 40.8mmol, 2M tetrahydrofuran solution), stir at -60°C for 2 hours, add methyl chloroformate (2.0g, 21.2mmol), after the addition is complete, stir at room temperature for 1 hour. TLC showed that the reaction was complete.
  • reaction solution was poured into water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried with anhydrous sodium sulfate, concentrated, and the crude silica gel column chromatography was used to obtain the title compound 16b (1.3 g, yield 44%) as a yellow liquid.
  • reaction solution was quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated and purified by silica gel column chromatography to obtain the title compound 16c (2.3g, yield 57%) as a yellow oily liquid .
  • reaction solution was added with water, extracted with ethyl acetate, and the organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain the title compound 17a (700 mg, yield 52%).
  • reaction solution was cooled to room temperature, water was added, extracted with ethyl acetate, the organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain the title compound 17b (250 mg, yield 59%).
  • DICEL AD-H 30*250mm, 5um, 30mL/min
  • IPA: Hexane 20:80
  • reaction solution was cooled to room temperature, water was added, extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, the residue was dissolved in tetrahydrofuran, diluted hydrochloric acid (2 mL, 3N) was added, and stirred at room temperature for 1 hour. TLC showed that the reaction was complete.
  • the reaction solution was extracted with ethyl acetate, the organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain the title compound 18a (493 mg, yield 62.9%).
  • Trimethylsilyl cyanide (7.1g, 71.57mmol) was dissolved in acetonitrile (200mL), tetrabutylammonium fluoride (18.7g, 71.52mmol) was added at room temperature, stirred for 10 minutes, compound 19b (12g, 47.82mmol) was added Acetonitrile (100 mL) solution. The reaction was carried out at room temperature for 2 hours, and TLC showed that the reaction was complete.
  • reaction solution was added with saturated sodium bicarbonate solution, extracted with ethyl acetate, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain the title compound 19c (4.58g, yield 48.6%) .
  • reaction solution was quenched with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain the title compound 19e (2.2 g, yield 50.3%).
  • 5-bromo-2-cyanopyridine 20a (5.0g, 27.32mmol) and pinacol diborate (13.9g, 54.74mmol) were dispersed in 1,4-dioxane (50mL), and acetic acid was added at room temperature Potassium (5.4g, 55.02mmol) and Pd(dppf)Cl 2 (500mg, 0.68mmol), under the protection of nitrogen, were heated to 100°C and reacted for 2 hours. TLC showed that the reaction was complete.
  • the reaction solution was cooled to room temperature, quenched with water, separated, the aqueous phase was extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated.
  • the crude product was purified by silica gel column chromatography to obtain the title compound 20b (3.5g). , The yield is 87%).
  • the third step ((5-(1-((5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3- (Yl)pyridin-2-yl)amino)-1-oxopropan-2-yl)-[2,3'-bipyridyl]-6'-yl)methyl)tert-butyl carbamate 20d
  • reaction solution was quenched with water, separated, the aqueous phase was extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography to obtain the title compound 20d (128mg, yield 22) as a pale yellow oil. %).
  • the first step (4-bromopyridin-2-yl) di-tert-butyl iminodicarbonate 21b
  • the second step (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)pyridin-2-yl) di-tert-butyl iminodicarbonate 21c
  • reaction solution was cooled to room temperature, water was added, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain the title compound 21c as a white solid (2.7g, yield 68%) .
  • reaction solution was cooled to room temperature, water was added, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain the title compound 21d (380 mg, yield 70%) as a white solid.
  • reaction solution was cooled to room temperature, diluted with water, extracted with ethyl acetate, combined the organic phases, dried over anhydrous sodium sulfate, concentrated, the residue was dissolved in tetrahydrofuran, added dilute hydrochloric acid (3mL, 3N), stirred at room temperature for 1 hour, TLC showed that the reaction was complete .
  • the reaction solution was extracted with ethyl acetate, the organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain the title compound 21f (2.27 g, yield 79.6%).
  • compound 21g (340mg, crude product) was dissolved in ethyl acetate (10mL), compound 21e (260mg, 1.35mmol), 1-propyl phosphoric anhydride (3.44g, 5.4mmol, 50% ethyl acetate) was added at room temperature Ester solution) and triethylamine (818 mg, 8.1 mmol) were heated to 60° C. and reacted for 2 hours. TLC showed that the reaction was complete.
  • reaction solution was diluted with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain the title compound 21h (224 mg, two-step yield 23%).
  • Step 8 (S)-N-(4-(5-cyano-2,2-dimethyl-2,3-dihydro-1H-pyrrolazine-7-yl)pyridin-2-yl)-2 -(6-(2-Hydroxypropan-2-yl)pyridin-2-yl)propionamide (hypothetical) 21-1&(R)-N-(4-(5-cyano-2,2-dimethyl -2,3-Dihydro-1H-pyrrolazine-7-yl)pyridin-2-yl)-2-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)propionamide (hypothetical) 21-2
  • the first step is ethyl 3-methyl-2-butenoate 22b
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography to obtain the title compound 22l (1.2g, yield 82%) .
  • Step 12 (S)-2-([2,3'-Bipyridyl]-5-yl)-N-(5-chloro-4-(6,6-dimethyl-6,7-dihydro -5H-Pyrrolo[1,2-a]imidazol-3-yl)pyridin-2-yl)propionamide (hypothetical) 22-1&(R)-2-([2,3'-bipyridine]-5 -Yl)-N-(5-chloro-4-(6,6-dimethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)pyridine-2- Base) propionamide (hypothetical) 22-2
  • Test Example 1 Test of the compound's inhibitory effect on CDK7/CDK9 in vitro enzyme activity
  • Compound preparation accurately weigh the compound and dissolve it with DMSO (Sigma, D2650) to a concentration of 10 mM for use. Dilute the compound to 5 times the required maximum concentration, and dilute 4 times into 6 concentration gradients, so that the final concentration of the compound in the reaction system is CDK7: 3000, 750, 188, 47, 12, 3nM; CDK9: 100, 25, 6.25 , 1.56, 0.39, 0.098nM. Transfer 5ul to a 384-well plate (Corning, 4512).
  • the compounds of the examples of the present invention have a significant inhibitory effect on CDK7/9 kinase activity.
  • Test Example 2 The effect of the compound on the inhibition of Mv4-11 cell proliferation
  • the inhibitory effect of the compound of the present invention on the proliferation of Mv4-11 cells (ATCC: CRL-9591 TM ) in vitro was determined by the following method:
  • Mv4-11 cells with good growth in log phase are seeded into a 96-well plate at 20,000 cells/well, 50uL, and cultured at 37°C and 5% CO 2 for 2-4 hours.
  • the inhibitory effect of the compound of the present invention on the downstream RNA pol II Ser2/5 of CDK7/CDK9 protein in Mv4-11 cells in vitro was determined by the following method:
  • Protein extraction and quantification Collect the cell suspension, centrifuge at 1000g for 5 minutes, discard the cell culture medium, add PBS to resuspend, centrifuge; repeat 3 times, suck up the remaining liquid, add 80uL cell lysate to each well, place on ice, shake Shake the bed for 10 minutes, centrifuge at 12000g for 5 minutes, and collect the supernatant, which is the total protein solution; the protein concentration is measured by the BCA method.
  • Figure 1 shows the phosphorylation results of compounds 2-2, 3, 11-2, 13-1, 13-2 and AZD4573 on RNA pol II Ser2/5.
  • the compounds of the present invention such as 2-2, 3, 11-2 and 13-2 have obvious phosphorylation of the downstream RNA pol II Ser5 of CDK7 protein in the acute myelocytic leukemia (AML) Mv4-11 cell line Inhibition; Compounds such as 2-2, 11-2 and 13-1 have obvious inhibitory effects on the phosphorylation of pol II Ser2 in the downstream RNA of CDK9 protein.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明属于吡啶乙酰胺类衍生物技术领域，具体涉及一种作为CDK抑制剂的吡啶乙酰胺类衍生物、其制备方法及应用。所述吡啶乙酰胺类衍生物表现出优异的CDK9/CDK7酶抑制活性，可用于制备治疗癌症的药物，所述癌症尤其是血液癌，包括急性髓细胞白血病、多发性骨髓瘤、慢性淋巴细胞性白血病、滤泡性淋巴瘤等和实体瘤，包括乳腺癌、前列腺癌、卵巢癌、肝细胞癌、胰腺癌、肾癌、胃癌、结直肠癌和肺癌等的治疗。

Description

一种作为CDK抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途 技术领域
本发明属于吡啶乙酰胺类衍生物技术领域，具体涉及一种作为CDK抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途。
背景技术
细胞周期依赖蛋白激酶(CDKs)是一类丝氨酸/苏氨酸激酶，在细胞周期调节及细胞转录过程中起着关键的作用，其作为治疗癌症和其他一些疾病的重要靶点受到越来越多的关注。CDKs家族共有13个结构类似的不同亚型，可以被10个左右的细胞周期蛋白激活，发挥不同的生物学功能。根据作用机制不同，一般分为细胞周期性CDK(CDK1-6)和转录性CDK(CDK7-9)。
CDK9主要参与转录调控过程，由CDK9和cyclin(T1、T2a、T2b、K)组成的异源二聚体参与组成正性转录延长因子(P-TEFb)，在转录调控过程中发挥关键作用。CDK9具有经典的蛋白激酶折叠，由C-端和N-端激酶域及一个小的C-端延伸区组成。CDK9作为P-TEFb的亚单位参与转录的延长过程，在转录过程中发挥重要作用。CDK9调控短寿命抗凋亡蛋白的RNA转录。CDK9通过磷酸化RNApol II来调控抗凋亡蛋白的表达。由RNApol II所催化的转录是一个多步骤过程。RNApol II大亚基的C端结构域包含串联的七肽重复序列上的Ser和Thr的磷酸化在转录过程中起重要作用。P-TEFb复合物中的CDK9磷酸化RNApol II CTD 2位Ser的同时，也会磷酸化敏感的诱导因子DSIF和负性延长因子NELF。磷酸化会使NELF离去，同时会使DSIF转化为正性转录因子，随后RNApol II进入转录延长模式，转录延长过程启动 1。
CDK7与cyclin H和Mat1形成了CDK激活激酶(CDK-activatig kinase,CAK)的催化中心，从而磷酸化CDK1，2，4和6来维持细胞周期的进程。另一方面，CAK是RNA多聚酶II(RNAPII)中转录因子TFIIH的组成部分，能够磷酸化RNAPII C端(CTD)的Rbp1亚基，而CTD的磷酸化对RNAPII的转录起到了调节的作用。而且CDK7能够通过T-loop的磷酸化来激活CDK9，从而进一步对转录起到调节的作用 2。
抑制CDK9会导致抗凋亡蛋白Mcl-1、XIAP等的下调，从而使这些抗凋亡蛋白失去维持肿瘤细胞稳定性的能力，进而诱导肿瘤细胞的凋亡。CDK9还参与许多细胞功能的调节。选择性地抑制CDK9还可以作为肿瘤侵袭和转移的潜在治疗策略。最近也有报道CDK9的抑制剂能够通过抑制转录和转录后修饰从而下调MYC蛋白，因此对MYC驱动的肿瘤有抑制的作用 3。此外抑制CDK9能够增加肿瘤环境中CD45 +细胞数，提高CD3 +T细胞的比例和激活树突细胞，因此联合CDK9的抑制剂能够增强肿瘤免疫检验点抑制剂(checkpoint blockage)的免疫响应 4。而CDK7的抑制也可以导致细胞周期的中断和基因的不稳定性，同时可以激活T细胞的免疫反应，也可以增强肿瘤免疫检验点抑制剂的免疫相应 5。
CDK作为治疗肿瘤和其他一些疾病的重要靶点，近20年来已有许多CDK抑制剂进入临床，并已有选择性CDK4/6抑制剂上市，这为研发选择性CDK抑制剂带来信心和希望。CDK9作为新颖和具有巨大潜力的抗肿瘤药物靶标，受到越来越多的关注，已有多个选择性CDK9抑制剂进入临床(Fadraciclib、Zotitraciclib、KB-130742和AZD-4573等)，以CDK9作为抗肿瘤药物靶标具有广阔应用前景。
目前一些CDK抑制剂对CDK7或CDK9等具有较高的选择性(WO2017001354，WO2018192273，WO2019154177等)。但这些现有技术中公开的化合物以及试验药物在有效性、安全性或选择性等方面依然存在不确定性，因此有必要研究和开发新的选择性的CDK抑制剂。
参考文献：
1、Boffo et al.CDK9 inhibitors in acute myeloid leukemia.J.Eep.Clin.Cancer Res.37,36(2018).
2、Kwak et al.Control of transcriptional elongation.Annu.Rev.Genet.47,483(2013).
3、Blake et al.Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.Sci.Signal.12,eeav7259(2019).
4、Zhang et al.Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.Cell 175,1244-1258(2018).
5、Zhang et al.CDK7 Inhibition Protentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.Cancer Cell.37,37-54(2020).
发明内容
为了解决现有技术的上述问题，本发明的目的在于提供一种吡啶乙酰胺类衍生物、其药学上可接受的盐、其互变异构体或其立体异构体，以筛选出在有效性、安全性和选择性等性能方面均具有优异性能的用作CDK家族包括但不限定于CDK9或CDK7抑制剂的化合物。
本发明的另一个目的是提供所述衍生物、其药学上可接受的盐、其互变异构体或其立体异构体的制备方法。
为达到此发明目的，本发明采用以下技术方案：
第一方面，本发明提供一种吡啶乙酰胺类衍生物、其药学上可接受的盐、其互变异构体或其立体异构体，所述吡啶乙酰胺类衍生物的结构如式(I)所示：
Figure PCTCN2021091707-appb-000001
其中：
R 1选自氢、卤素、氰基、取代或未取代的C 1-C 3的烷基或取代或未取代的C 1-C 3的烷氧基，其中此处“取代”是指任选地进一步被1-3个卤素取代；
R 21和R 22分别独立的选自氢、卤素、羟基、氰基、氨基、取代或未取代的C 1-C 3烷基以及取代或未取代的C 1-C 3烷氧基，其中，此处取代是指任选被1-3个卤素、羟基、氰基或氨基取代；
AR 1选自苯基、5-6元的杂芳基、8-10元的稠芳基和8-10元的稠杂芳基，且其中苯基、5-6元的杂芳基、8-10元的稠芳基和8-10元的稠杂芳基任选地进一步被一个或多个R a所取代；
R a独立地选自C 1-C 3烷基、羟基、卤素、氰基、氨基、C 1-C 3烷氧基、C 3-C 6环烷基、C 3-C 6杂环基、苯基、5-6元的杂芳基、S(O)R b1、S(O) 2R b1、S(O)NH 2、S(O)NHR b1、S(O)NR b1R b2、S(O) 2NH 2、S(O) 2NHR b1、S(O) 2NR b1R b2、NHS(O)R b1、NR b1S(O)R b2、NHS(O) 2R b1、NR b1S(O) 2R b2、C(O)R b1、C(O)OR b1、OC(O)R b1、NHC(O)R b1、NR b1C(O)R b2、NHC(O)OR b1、NR b1C(O)OR b2、C(O)NH 2、C(O)NHR b1、C(O)NR b1R b2，其中的烷基、烷氧基、环烷基、杂环基、苯基、5-6元的杂芳基任选进一步被1-3个烷基、羟基、卤素、氰基、氨基、烷氧基、丙烯酰基或丙烯酰亚甲基所取代；
R b1和R b2分别独立地选自C1-C 3的烷基、3-6元的环烷基或杂环基，其中的烷基，环烷基和杂环基任选进一步被1-3个选自烷基、羟基、卤素、氰基、氨基或烷氧基的取代基所取代，或者R b1和R b2连同它们所连接的N原子形成3-7元的杂环基；
R 3选自：
Figure PCTCN2021091707-appb-000002
Z为N或CR c；
R c独立地选自氢、卤素、氰基、C(O)NH 2、C(O)NHR b、C(O)NR b1R b2、C(O)R b或C1-C 3的烷基，其中的烷基任选进一步被1-3个选自烷基、羟基、卤素、氰基、氨基或烷氧基的取代基所取代；
X和Y连同它们附接的原子一起形成5-7元杂环基或环烷基，其中杂环基包括1-2个选自N、O、S的杂原子；该5-7元杂环基或环烷基是饱和的或者是部分饱和的而且其中的环碳或环S原子任选进一步被1-3个R d取代；
R d独立地选自卤素、羟基、氰基、＝O或C1-C 3的烷基，其中的烷基任选进一步被1-3个选自烷基、羟基、卤素、氰基、氨基或烷氧基的取代基所取代；
Figure PCTCN2021091707-appb-000003
优选地，所述吡啶乙酰胺类衍生物的结构如式(Ⅱ)所示：
其中，R 1、R 21、R 22、AR 1和R c具有与上述通式(I)相同的限定范围。
优选地，所述吡啶乙酰胺类衍生物的结构如式(III)所示：
其中，R 1、R 21、R 22、AR 1和R c具有与上述通式(I)相同的限定范围。
优选地，所述吡啶乙酰胺类衍生物的结构如式(IV)所示：
其中，R 1、R 21、R 22和AR 1具有与上述通式(I)相同的限定范围。
优选地，所述吡啶乙酰胺类衍生物的结构如式(V)所示：
其中，R 1、R 21、R 22和AR 1具有与上述通式(I)相同的限定范围。
进一步优选地，所述吡啶乙酰胺类衍生物选自如下结构的任意一种：
Figure PCTCN2021091707-appb-000004
Figure PCTCN2021091707-appb-000005
Figure PCTCN2021091707-appb-000006
Figure PCTCN2021091707-appb-000007
Figure PCTCN2021091707-appb-000008
第二方面，本发明提供一种如第一方面所述的吡啶乙酰胺类衍生物、其药学上可接受的盐、其互变异构体或其立体异构体的制备方法，其选自如下三种方案中的一种：
方案一
Figure PCTCN2021091707-appb-000009
第一步，通式(I-1)的化合物在碱性条件下，胺基Boc保护，得到通式(I-2)的化合物；
第二步，通式(I-2)的化合物在碱性条件下，在金属催化剂的存在下，得到通式(I-3)的化合物；
第三步，通式(I-3)的化合物和通式(I-4)的化合物在碱性条件下，在金属催化剂和配体的存在下经Suzuki反应，得到通式(I-5)的化合物；
第四步，通式(I-5)的化合物在酸性条件下，脱去Boc保护基得到通式(I-A)的化合物；
第五步，通式(I-A)的化合物和通式(I-B)的化合物在碱性条件下，经缩合反应得到通式(I)的化合物。
其中，R 1、AR 1、R 21、R 22和R 3具有与上述通式(I)相同的限定范围。
方案二
Figure PCTCN2021091707-appb-000010
第一步，通式(I-4)的化合物在碱性条件下，在金属催化剂的存在下，得到通式(I-Bb)的化合物；
第二步，通式(I-1)的化合物和通式(I-B)的化合物在碱性条件下，经缩合反应得到通式(I-Aa)的化合物；
第三步，通式(I-Aa)的化合物和通式(I-Bb)的化合物在碱性条件下，在金属催化剂和配体的存在下经Suzuki反应，得到通式(I)的化合物。
其中，X为卤素，优选为溴；W为
Figure PCTCN2021091707-appb-000011
R 1，AR 1，R 21，R 22和R 3具有与上述通式(I)相同的限定范围。
方案三
Figure PCTCN2021091707-appb-000012
第一步，通式(I-B)的化合物和氯化铵在碱性条件下，经缩合反应得到通式(I-Bbb)的化合物；或者，通式(I-6)的化合物在碱性条件下，经氧化得到通式(I-Bbb)的化合物；
第二步，通式(I-7)的化合物和通式(I-Bb)的化合物在碱性条件下，在催化剂存在下经Suzuki反应，得到通式(I-Aaa)的化合物；
第三步，通式(I-Aaa)的化合物和通式(I-Bbb)的化合物在碱性条件下，经缩合反应得到通式(I)的化合物。
其中，X为卤素，优选为氯；R 1，AR 1，R 21，R 22和R 3具有与上述通式(I)相同的限定范围。
对于上述制备方法中，提供碱性条件的试剂选自有机碱或无机碱类，所述的有机碱类包括但不限于三乙胺、N,N-二异丙基乙胺、正丁基锂、二异丙基氨基锂、双三甲基硅基胺基锂、醋酸钾、醋酸钠、叔丁醇钠、甲醇钠和叔丁醇钾中的一种或多种，所述的无机碱类为氢化钠、磷酸钾、碳酸钠、碳酸钾、醋酸钾、碳酸铯、氢氧化钠、氢氧化钾、碳酸氢钠和氢氧化锂中的一种或多种；
提供酸性条件的试剂包括但不限于氯化氢、氯化氢的1,4-二氧六环溶液、三氟乙酸、甲酸、乙酸、盐酸、硫酸、甲磺酸、硝酸和磷酸中的一种或多种；
金属催化剂包括但不限于钯/碳、雷尼镍、四-三苯基膦钯、二氯化钯、醋酸钯、[1,1'-双(二苯基膦基)二茂铁]二氯化钯(Pd(dppf)Cl 2)、[1,1'-双(二苯基膦基)二茂铁]二氯化钯二氯甲烷络合物、双三苯基磷二氯化钯(Pd(PPh 3)Cl 2)和三(二亚苄基丙酮)二钯(Pd 2(dba) 3)中的一种或多种；
配体包括但不限于2-双环己基膦-2,6'-二甲氧基联苯(SPhos)、4,5-双二苯基膦-9,9-二甲基氧杂蒽(XantPhos)、2-二环己基磷-2,4,6-三异丙基联苯(XPhos)、2-二环己膦基-2'-(N,N-二甲胺)-联苯(DavePhos)、1,1'-双(二苯基膦)二茂铁(Dppf)和1,1'-联萘-2,2'-双二苯膦(BINAP)中的一种或多种，优选为4,5-双二苯基膦-9,9-二甲基氧杂蒽(XantPhos)；
缩合剂包括但不限于二环己基碳二亚胺(DCC)、二异丙基碳二亚胺(DIC)、1-(3-二甲胺基丙基)-3-乙基碳二亚胺(EDC)、1-(3-二甲氨基丙基)-3-乙基碳二亚胺(EDCI)、2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU)，2-(1H-苯并三偶氮L-1-基)-1,1,3,3-四甲基脲四氟硼酸酯(TBTU)，1-羟基苯并三唑(HOBt)和1-丙基磷酸酐(T3P)中的一种或多种。
上述反应优选在溶剂中进行，所用溶剂包括但不限于：N,N-二甲基甲酰胺、二甲基亚砜、1,4-二氧六环、水、四氢呋喃、二氯甲烷、1,2-二氯乙烷、醋酸、甲醇、乙醇、甲苯、石油醚、乙酸乙酯、正己烷、丙酮、乙醚、二甘醇及其混合物。
第三方面，本发明提供一种药物组合物，所述药物组合物包括如上所述的吡啶乙酰胺类衍生物、立体异构体、互变异构体、可药用盐；
优选地，所述药物组合物还包括可药用载体和/或赋形剂。
第四方面，本发明提供一种如第一方面所述的吡啶乙酰胺类衍生物、立体异构体、互变异构体、可药用盐或如第三方面所述的药物组合物在制备用于治疗癌症的药物或在制备CDK家族抑制剂中的用途，其中所述的癌症，优选血液癌，包括急性髓细胞白血病、多发性骨髓瘤、慢性淋巴细胞性白血病、滤泡性淋巴瘤等和实体瘤，包括乳腺癌、前列腺癌、卵巢癌、肝细胞癌、胰腺癌、肾癌、胃癌、结直肠癌和肺癌等。
本发明还提供用作CDK抑制剂的吡啶乙酰胺类衍生物用于治疗癌症的方法，该方法是通过向患有癌症的受试者给予一个有效量的所述的化合物进行的。
本发明的这些化合物可以进一步与治疗有效量的一种或多种治疗癌症的试剂组合来给予，其中这些试 剂的实例包括，例如辐射、烷化剂、血管生成抑制剂、抗有丝分裂剂、抗增生剂、极光激酶抑制剂、细胞死亡活化剂(例如，Bcl-2、BclxL、Bcl-w、Bfl-1、或Mcl-1的抑制剂)、死亡受体途径的活化剂、Bcr-Abl激酶抑制剂、BET(溴结构域蛋白)抑制剂、Ras信号通路抑制剂(例如MEK、Raf或Ras的抑制剂)、抗体、BiTE(双特异性T细胞接合器)抗体、抗体药物偶联物、生物应答调节剂、细胞周期蛋白依赖性激酶抑制剂、细胞周期抑制剂、环氧合酶-2抑制剂、DVD(双重可变结构域抗体)、白血病病毒癌基因同系物(ErbB2)受体抑制剂、生长因子抑制剂、热休克蛋白(HSP)-90抑制剂、组蛋白脱乙酰基酶(HDAC)抑制剂、激素疗法、免疫药、细胞凋亡蛋白的抑制剂(IAP)、激酶抑制剂、肿瘤驱动蛋白抑制剂、Jak2抑制剂、哺乳动物雷帕霉素靶蛋白抑制剂、微小RNA、丝裂原激活胞外信号-调节的激酶抑制剂、聚ADP(腺苷二磷酸)-核糖聚合酶(PARP)抑制剂、铂化疗剂、polo样激酶(Plk)抑制剂、磷酸肌醇-3激酶抑制剂、蛋白酶体抑制剂、小抑制核糖核酸酸类(siRNA)、拓扑异构酶抑制剂、泛素连接酶抑制剂、以及类似物，以及这些试剂的一种或多种组合。
如在此所使用的，术语“有效量”意指一种化合物或组合物的足以显著和积极改变有待治疗的症状和/或病症(例如，提供积极临床响应)的量。用于一种药物组合物中的活性成分的有效量将随着正在被治疗的具体病症、该病症的严重性，治疗的持续时间、同步治疗的性质，该一种或多种使用的具体的活性成分，一种或多种所使用的药学上可接受的赋形剂/载体、以及主治医生的知识和专业技能内的类似因素而变化。
具体地，用于在癌症治疗中使用的具有化学式(I)的化合物的一个有效量是足以对症减轻在人中癌症的症状的量，以减缓癌症的进展，或减少患有癌症的患者中症状恶化的风险。
术语解释
除非有相反陈述，否则本发明在说明书和权利要求书中所使用的部分术语定义如下：
“烷基”指饱和脂肪族烃基团，包括1-20个碳原子，或1-10个碳原子，或1-6个碳原子，或1-4个碳原子，或1-3个碳原子，或1-2个碳原子饱和直链或支链的单价烃基，其中烷基可以独立任选地被一个或多个本发明所描述地取代基所取代。烷基基团更近一步地实例包括，包括但不限于甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。烷基可以是任选取代或未取代的。
“烯基”指2-12个碳原子，或2-8个碳原子，或2-6个碳原子，或2-4个碳原子直链或支链的一价烃基，其中至少一个C-C为sp 2双键，其中烯基的基团可以独立任选地被1个或多个本发明所描述的取代基所取代，其中具体的实例包括，但并不限于乙烯基、烯丙基和烯丁基等等。烯基可以是任选取代或未取代的。
“环烷基”是指饱和或部分不饱和单环或多环环状烃取代基，环烷基环包括3至20个碳原子，优选包括3至12个碳原子，更优选包含3至6个碳原子。单环环烷基的非限制性实施例包括，但不限于环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等；多环环烷基包括螺环、稠环和桥环的环烷基。环烷基可以是任选取代的或未取代的。
“螺环烷基”指5至18元，两个或两个以上环状结构，且单环之间彼此共用一个碳原子(称螺原子)的多环基团，环内含有1个或多个双键，但没有一个环具有完全共轭的π电子的芳香系统。优选为6至14元，更优选为7至10元。根据环与环之间共用螺原子的数目将螺环烷基分为单螺、双螺或多螺环烷基，优选为单螺和双螺环烷基，优选为4元/5元、4元/6元、5元/5元或5元/6元。“螺环烷基”的非限制性实施例包括但不限于：
Figure PCTCN2021091707-appb-000013
“稠环烷基”指5至18元，含有两个或两个以上环状结构彼此公用一对碳原子的全碳多环基团，一个或多个环可以含有一个或多个双键，但没有一个环具有完全共轭的π电子的芳香系统，优选为6至12元，更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环稠环烷基，优选为双环或三环，更优选为5元/5元或5元/6元双环烷基。“稠环烷基”的非限制性实施例包括但不限于：
Figure PCTCN2021091707-appb-000014
“桥环烷基”指5至18元，含有两个或两个以上环状结构，彼此共用两个不直接相连接碳原子的全碳多环基团，一个或多个环可以含有一个或多个双键，但没有一个环具有完全共轭的π电子的芳香系统，优选 为6至12元，更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环桥环烷基，优选为双环、三环或四环，更有选为双环或三环。“桥环烷基”的非限制性实施例包括但不限于：
Figure PCTCN2021091707-appb-000015
所述环烷基环可以稠合于芳基、杂芳基或杂环基环上，其中与母体结构连接在一起的环为环烷基，非限制性实施例包括茚满基、四氢萘基、苯并环庚烷基等。
“杂环基”、“杂环”或“杂环的”在本申请中可交换使用，本申请中可交换使用，都是指包含3-12个环原子的饱和或部分不饱和的单环、双环或三环的非芳香性杂环基，其中至少一个环原子原子是杂原子，如氧、氮、硫原子等。优选具有5至7元单环或7至10元双-或三环，其可以包含1，2或3个选自氮、氧和/或硫中的原子。“杂环基”的实例包括但不限于吗啉基，氧杂环丁烷基，硫代吗啉基，四氢吡喃基，1，1-二氧代-硫代吗啉基，哌啶基，2-氧代-哌啶基，吡咯烷基，2-氧代-吡咯烷基，哌嗪-2-酮，8-氧杂-3-氮杂-双环[3.2.1]辛基和哌嗪基。所述杂环基环可以稠合于芳基、杂芳基或环烷基环上，其中与母体结构连接在一起的环为杂环基。杂环基可以是任选取代的或未取代的。
“螺杂环基”指5至18元，两个或两个以上环状结构，且单环之间彼此共用一个原子的多环基团，环内含有1个或多个双键，但没有一个环具有完全共轭的π电子的芳香系统，其中一个或多个环原子选自氮、氧、硫或S(O) m的杂原子，其余环原子为碳，m＝1或2。优选为6至14元，更优选为7至10元。根据环与环之间共用螺原子的数目将螺杂环基分为单螺杂环基、双螺杂环基或多螺杂环基，优选为单螺杂环基和双螺杂环基。更优选为4元/4元、4元/5元、4元/6元、5元/5元或5元/6元单螺杂环基。“螺杂环基”的非限制性实施例包括但不限于：
Figure PCTCN2021091707-appb-000016
“稠杂环基”指含有两个或两个以上环状结构彼此公用一对原子的全碳多环基团，一个或多个环可以含有一个或多个双键，但没有一个环具有完全共轭的π电子的芳香系统，其中一个或多个环原子选自氮、氧、硫或S(O) m的杂原子，其余环原子为碳，m＝1或2。优选为6至14元，更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环稠杂环基，优选为双环或三环，更优选为5元/5元或5元/6元双环稠杂环基。“稠杂环基”的非限制性实施例包括但不限于：
Figure PCTCN2021091707-appb-000017
“桥杂环基”指5至18元，含有两个或两个以上环状结构，彼此共用两个不直接相连接的原子的多环基团，一个或多个环可以含有一个或多个双键，但没有一个环具有完全共轭的π电子的芳香系统，其中一个或多个环原子选自氮、氧、硫或S(O) m的杂原子，其余环原子为碳，m＝1或2。优选为6至14元，更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环桥杂环基，优选为双环、三环或四环，更有选为双环或三环。“桥杂环基”的非限制性实施例包括但不限于：
Figure PCTCN2021091707-appb-000018
“芳基”是指含有一个或者两个环的碳环芳香系统，其中所述环可以以稠合的方式连接在一起。术语“芳基”包括比如苯基、萘基、四氢萘基的芳香基团。优选芳基为C 6-C 10芳基，更优选芳基为苯基和萘基，最优选为苯基。芳基可以是取代或未取代的。所述“芳基”可与杂芳基、杂环基或环烷基稠合，其中与母体结构连接在一起的为芳基环，非限制性实施例包括但不限于：
Figure PCTCN2021091707-appb-000019
“杂芳基”是指芳香族5至6元单环或9至10元双环，其可以包含1至4个选自氮、氧和/或硫中的原子。“杂芳基”的实施例包括但不限于呋喃基，吡啶基，2-氧代-1，2-二氢吡啶基、哒嗪基、嘧啶基、吡嗪基、噻吩基、异噁唑基、噁唑基、噁二唑基、咪唑基、吡咯基、吡唑基、三唑基、四唑基、噻唑基、异噻唑基、1，2，3-噻二唑基、苯并间二氧杂环戊烯基、苯并咪唑基、吲哚基、异吲哚基、1，3-二氧代-异吲哚基、喹啉基、吲唑基、苯并异噻唑基、苯并噁唑基和苯并异噁唑基。杂芳基可以是任选取代或未取代的。所述杂芳基环可以稠合于芳基、杂环基或环烷基环上，其中与母体结构连接在一起的环为杂芳基环，非限制性实施例包括但不限于：
Figure PCTCN2021091707-appb-000020
“烷氧基”是指(烷基-O-)的基团。其中，烷基见本文有关定义。C 1-C 6的烷氧基为优先选择。其实例包括，但不限于：甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、异丁氧基、叔丁氧基等。
“卤代烷基”指具有一个或者多个卤素取代基的烷基，其中烷基基团具有如本发明所述的含义。卤代烷基的实例包括，但并不限于氟甲基、二氟甲基、三氟甲基、全氟乙基、1,1-二氯乙基、1,2-二氯丙基等。
“羟基”指-OH基团。
“卤素”是指氟、氯、溴和碘，优选氟、氯和溴。
“氨基”指-NH 2。
“氰基”指-CN。
“硝基”指-NO 2。
“苄基”指-CH 2-苯基。
“羧基”指-C(O)OH。
“乙酰基”指-C(O)CH 3或Ac。
“羧酸酯基”指-C(O)O(烷基)或(环烷基)，其中烷基、环烷基的定义如上所述。
“任选”意味着其所描述的事件可以但不必发生。例如，“AR 1任选被1到多个R c取代”该说明包含着AR 1基团可以被1到多个R c取代或者不被R c取代的情形。
“取代的”指基团中的一个或多个氢原子，优选为最多5个，更优选为1-3个氢原子彼此独立地被相应数目的取代基取代。不言而喻，取代基仅处在它们的可能的化学位置，本领域技术人员能够在不付出过多努力的情况下确定(通过实验或理论)可能或不可能的取代。例如，具有游离氢的氨基或羟基与具有不饱和(如烯属)键的碳原子结合时可能是不稳定的。
本说明书所述的“取代”或“取代的”，如无特别指出，均是指基团可被一个或多个选自以下的基团取代：烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、疏基、羟基、硝基、氰基、环烷基、杂环基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氨基、卤代烷基、羟烷基、羧基、羧酸酯基、＝O、-C(O)R b、-OC(O)R b、-NR bR b、-C(O)NR bR b、-NR bC(O)R b、-S(O)NR bR b或-S(O) 2NR bR b，其中，R b的定义如通式(I)中所述。
本发明中立体化学的定义和惯例的使用通常参考以下文献：
S.P.Parker,Ed.,McGraw-Hill Dictionary of Chemical Terms(1984)McGraw-HillBook Company,New York；and Eliel,E.and Wilen,S.,"Stereochemistry of Organic Compounds",John Wiley&Sons,Inc.,New York,1994.本发明的化合物可以包含不对称中心或手性中心，因此存在不同的立体异构体。本发明的化合物所有的立体异构形式，包括但绝不限于，非对映体，对映异构体，阻转异构体，和它们的混合物，如外消旋混合物，组成了本发明的一部分。非对映异构体可以以其物理化学差异为基础，通过层析、结晶、蒸 馏或升华等方法被分离为个别非对映异构体。对映异构体可以通过分离，使手性异构混合物转化为非对映异构混合物，其方式是与适当光学活性化合物(例如手性辅助剂，譬如手性醇或Mosher氏酰氯)的反应，分离非对映异构体，且使个别非对映异构体转化为相应的纯对映异构体。本发明的中间体与化合物也可以不同互变异构形式存在，且所有此种形式被包含在本发明的范围内。很多有机化合物都以光学活性形式存在，即它们有能力旋转平面偏振光的平面。在描述光学活性化合物时，前缀D、L或R、S用来表示分子手性中心的绝对构型。前缀d、l或(+)、(-)用来命名化合物平面偏振光旋转的符号，(-)或l是指化合物是左旋的，前缀(+)或d是指化合物是右旋的。这些立体异构体的原子或原子团互相连接次序相同，但是它们的立体结构不一样。特定的立体异构体可以是对映体，异构体的混合物通常称为对映异构体混合物。50：50的对映体混合物被称为外消旋混合物或外消旋体，这可能导致化学反应过程中没有立体选择性或立体定向性。术语“外消旋混合物”和“外消旋体”是指等摩尔的两个对映异构体的混合物，缺乏光学活性。
“互变异构体”或“互变异构的形式”是指不同能量的结构的同分异构体可以通过低能垒互相转化。例如质子互变异构体(即质子移变的互变异构体)包括通过质子迁移的互变，如酮式-烯醇式和亚胺-烯胺的同分异构化作用。原子价(化合价)互变异构体包括重组成键电子的互变。除非其他方面表明，本发明所描述的结构式包括所有的同分异构形式(如对映异构，非对映异构，和几何异构)：例如含有不对称中心的R、S构型，双键的(Z)、(E)异构体，和(Z)、(E)的构象异构体。因此，本发明的化合物的单个立体化学异构体或其对映异构体，非对映异构体，或几何异构体的混合物都属于本发明的范围。
“可药用盐”指本发明化合物的盐，这类盐用于人或动物体内时具有安全性和有效性。化合物的盐可以通过在纯的溶液或合适的惰性溶解中用足量的碱或酸获得相应的加成盐。可药用的碱加成盐包括钠、钾、钙、铵、有机氨或镁盐等，可药用的酸加成盐包括无机酸盐和有机酸盐，所述的无机酸和有机酸包括盐酸、氢溴酸、碳酸、碳酸氢根、磷酸、磷酸一氢根、磷酸二氢根、硫酸、硫酸一氢根、乙酸、马来酸、丙二酸、琥珀酸、饭丁烯二酸、邻苯二甲酸、苯磺酸、对甲苯磺酸、柠檬酸和甲磺酸等(参见Berge et al.,“Pharmaceutical Salts”,Journal of Pharmaceutical Science 66:1-19(1977))。
与现有技术相比，本发明提供的用作CDK抑制剂的吡啶乙酰胺类衍生物具有如下有益效果：
本发明提供了一种新结构的CDK抑制剂，试验结果表明，该吡啶乙酰胺类衍生物表现出优异的CDK7/CDK9酶抑制活性，可用于制备治疗癌症，尤其是血液癌，包括急性髓细胞白血病、多发性骨髓瘤、慢性淋巴细胞性白血病、滤泡性淋巴瘤等和实体瘤，包括乳腺癌、前列腺癌、卵巢癌、肝细胞癌、胰腺癌、肾癌、胃癌、结直肠癌和肺癌等疾病的药物。
附图说明
图1为化合物2-2、3、11-2、13-1、13-2和AZD4573对Mv4-11细胞RNA pol II Ser2/5的磷酸化抑制作用SDS-PAGE电泳检测图。
具体实施方式
下面通过具体实施例对本发明的方法进行说明，以使本发明技术方案更易于理解、掌握，但本发明并不局限于此。下述实施例中 1H NMR图谱是用Bruker仪器(400MHz)测定而得，化学位移用ppm表示。使用四甲基硅烷内标准(0.00ppm)。 1H NMR的表示方法：s＝单峰，d＝双重峰，t＝三重峰，q＝四重峰，m＝多重峰，br＝变宽的，dd＝双重峰的双重峰，dt＝三重峰的双重峰。若提供偶合常数时，其单位为Hz。
质谱是用LC/MS仪测定得到，离子化方式为ESI。
高效液相色谱仪型号：安捷伦1260、赛默飞U3000；色谱柱型号：Waters xbrige C18(4.6*150mm,3.5μm)；流动相：A:ACN,B:Water(0.1％H 3PO 4)；流速：1.0mL/min；梯度：5％A for 1min,increase to 20％A within 4min,increase to 80％A within 8min,80％A for 2min,back to 5％A within 0.1min；波长：220nm；柱温箱：35℃。
薄层层析硅胶板使用烟台黄海HSGF254或青岛GF254硅胶板，薄层色谱法(TLC)使用的硅胶板采用的规格是0.2mm-0.3mm，薄层层析分离纯化产品采用的规格是0.4mm-0.5mm。
柱层析一般使用烟台黄海硅胶200-300目硅胶为载体。
在下列实例中，除非另有指明，所有温度为摄氏温度，除非另有指明，各种起始原料和试剂来自市售或者是根据已知的方法合成，市售原料和试剂均不经进一步纯化直接使用，除非另有指明，市售厂家包括但不限于国药集团，百灵威科技有限公司，梯希爱(上海)化成工业发展有限公司，上海毕得医药科技有限公司和上海迈瑞尔化学科技有限公司等。
CD 3OD：氘代甲醇
CDCl 3：氘代氯仿
DMSO-d 6：氘代二甲基亚砜
Pd 2(dba) 3：三(二亚苄基丙酮)二钯
Pd(dppf)Cl 2：[1,1'-双(二苯基膦基)二茂铁]二氯化钯
XantPhos：4,5-双二苯基膦-9,9-二甲基氧杂蒽
XPhos：2-二环己基磷-2,4,6-三异丙基联苯
HATU：2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯
TLC：薄层色谱法
HPLC：高效液相色谱法
purity：纯度
&：和
氢气氛围是指反应瓶连接一个约1L容积的氢气气球。
实施例中无特殊说明，反应中的溶液是指水溶液。
实施例中无特殊说明，反应的温度为室温，为20℃-30℃。
实施例中的反应进程的监测采用薄层色谱法(TLC)，反应所使用的展开剂，纯化化合物采用的柱层析的洗脱剂的体系或薄层色谱法的展开剂体系包括：A：石油醚和乙酸乙酯体系；B：二氯甲烷和甲醇体系；C：正己烷：乙酸乙酯；其中溶剂的体积比根据化合物的极性不同而不同，也可以加入少量的酸性或碱性试剂进行调节，如醋酸或三乙胺等。
中间体的制备
中间体1
5,5-二甲基-3-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)-5,6-二氢-4H-吡咯并[1,2-b]吡唑IN-1
Figure PCTCN2021091707-appb-000021
第一步羟基三甲基乙酸甲酯IN-1b
2,2-二甲基-3-羟基丙酸IN-1a(100.0g,0.85mol)溶于甲醇(1L)中，室温下滴加浓硫酸(91.1g,0.36mol)，加完升温至75℃反应4小时，TLC显示反应完全。反应液浓缩，加饱和碳酸氢钠水溶液调节pH至弱碱，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得淡黄色透明液体标题化合物IN-1b(93.0g,粗品)，直接用于下一步。
第二步2,2-二甲基-3-((甲基磺酰基)氧基)丙酸甲酯IN-1c
化合物IN-1b(93.0g,粗品)溶于二氯甲烷(500mL)中，加入三乙胺(85.9g,0.85mol)，降温至-5℃，氮气保护下，滴加甲基磺酰氯(88.2g,0.77mol)，加完升至室温反应2小时，TLC显示反应完全。反应液倒入水中，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得淡黄色透明液体标题化合物IN-1c(121.0g,粗品)，直接用于下一步。
第三步3-溴-2,2-二甲基丙酸甲酯IN-1d
化合物IN-1c(121.0g,粗品)溶于N,N-二甲基甲酰胺(800mL)中，室温下加入溴化锂(101.0g,1.16mol)，升温至100℃反应过夜，TLC显示反应完全。反应液冷却至室温，倒入水中，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得淡黄色透明液体标题化合物IN-1d(85.0g,三步收率51％)。
1H NMR(400MHz,CDCl 3)δ3.69(s,3H),3.48(s,2H),1.29(s,6H).
第四步2,2-二甲基-3-(1H-吡唑-1-基)丙酸甲酯IN-1e
化合物IN-1d(85.0g,0.44mol)溶于N,N-二甲基甲酰胺(500mL)中，室温下加入碳酸铯(173.0g,0.53mol)和咪唑(32.6g,0.48mol)，升温至85℃反应过夜，TLC显示反应完全。反应液冷却至室温，倒入水中，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得淡黄色透明液体标题化合物IN-1e(41.0g,收率52％)。
LC-MS:m/z＝183.2[M+H] +
第五步2,2-二甲基-3-(1H-吡唑-1-基)丙酸IN-1f
化合物IN-1e(41.0g,0.22mol)溶于四氢呋喃(150mL)和甲醇(100mL)的混合溶剂中，加入氢氧化钠(18.0g,0.45mol)的水(100mL)溶液，室温搅拌1小时，TLC显示反应完全。反应液浓缩去除四氢呋喃和甲醇，加水，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得白色固体标题化合物IN-1f(33.0g,粗品)，直接用于下一步。
1H NMR(400MHz,DMSO-d 6)δ12.44(s,1H),7.61(t,J＝1.6Hz,1H),7.41(d,J＝1.6Hz,1H),6.21(t,J＝2.0Hz,1H),4.24(s,2H),1.06(s,6H).
第六步5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-4-酮IN-1g
化合物IN-1f(33.0g,粗品)溶于无水四氢呋喃(300mL)中，氮气保护下，降温至-65℃，缓缓滴加正丁基锂(160mL,0.4mol,2.5M四氢呋喃溶液)，滴完升温至-45℃反应1小时，再升至室温搅拌过夜，TLC显示反应完全。反应液缓缓倒入水中，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得淡黄色液体标题化合物IN-1g(18.1g,两步收率55％)。
第七步5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑IN-1h
化合物IN-1g(18.1g,0.12mol)溶于二甘醇(300mL)中，室温下加入水合肼(30mL,0.6mol,85％)，升温至180℃(内温156℃)反应2小时，降温至150℃，缓慢加入氢氧化钾(23.6g,0.42mol)，加完升温至180℃反应5小时，TLC显示反应完全。反应液冷却至室温，加水，加盐酸(3M)溶液调节pH＝6-7，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得到淡黄色液体标题化合物IN-1h(7.8g,收率48％)。
第八步3-溴-5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑IN-1i
化合物IN-1h(7.1g,52.1mmol)溶于二氯甲烷(60mL)中，加入N-溴代丁二酰亚胺(9.3g,52.2mmol)，室温反应过夜，TLC显示反应完全。反应液加水，二氯甲烷萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得到黄色液体标题化合物IN-1i(7.8g,收率48％)。
第九步5,5-二甲基-3-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)-5,6-二氢-4H-吡咯并[1,2-b]吡唑IN-1
化合物IN-1i(5.5g,25.6mmol)溶于1,4-二氧六环(50mL)中，加入联硼酸频那醇酯(9.7g,38.2mmol)、醋酸钾(5.0g,51.0mmol)和Pd(dppf)Cl 2二氯甲烷络合物(244mg,0.3mmol)，氮气保护下，升温至85℃反应过夜，TLC显示反应完全。反应液冷却至室温，加水，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得到淡黄色液体标题化合物IN-1(2.4g,收率36％)。
1H NMR(400MHz,CDCl 3)δ7.77(s,1H),3.88(s,2H),2.79(s,2H),1.26(s,12H),1.24(s,6H).
中间体2
5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-胺IN-2
Figure PCTCN2021091707-appb-000022
第一步(4-溴-5-氯吡啶-2-基)亚氨基二碳酸二叔丁酯IN-2b
4-溴-5-氯吡啶-2-氨基IN-2a(3.0g,14.5mmol)分散在叔丁醇/丙酮(1:1)的混合溶剂(100mL)中，加入三乙胺(6.2g,61.3mmol)，二碳酸二叔丁酯(12.7g,58.2mmol)和4-二甲氨基吡啶(催化量)，室温搅拌3小时，TLC显示原料反应完全。反应液浓缩除去有机溶剂，加水稀释，乙酸乙酯萃取，合并有机相，饱和盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得白色固体标题化合物IN-2b(7.5g,粗品)，直接用于下一步。
1H NMR(400MHz,DMSO-d 6)δ8.65(s,1H),8.03(s,1H),1.41(s,18H).
第二步(2-((二叔丁氧基羰基)氨基)-5-氯吡啶-4-基)硼酸IN-2c
化合物IN-2b(1.0g,粗品)分散在1,4-二氧六环(20mL)中，依次加入联硼酸频那醇酯(950mg,3.7mmol)，乙酸钾(730mg,7.4mmol)和Pd(dppf)Cl 2二氯甲烷络合物(催化量)，氮气保护下，升温至90℃搅拌1小时，TLC显示原料消失。反应液冷却至室温，过滤，滤饼乙酸乙酯洗涤，滤液加水稀释，乙酸乙酯萃取，合并有机相，水洗，饱和盐水洗，无水硫酸钠干燥，浓缩得褐色油状物标题化合物IN-2c(2.5g,粗品)直接用于下一步。
LC-MS:m/z＝373.1[M+H] +
第三步(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)亚氨基二碳酸二叔丁酯IN-2d
化合物IN-1i(215mg,1.0mmol)和化合物IN-2c(746mg,2.0mmol)分散在1,4-二氧六环(15mL)和水(5mL)中，室温下依次加入碳酸钠(212mg,2.0mmol)和Pd(dppf)Cl 2(催化量)，加毕，氮气保护下升温至100℃搅拌1小时，TLC显示原料反应完全。反应液冷却至室温，过滤，滤饼乙酸乙酯洗涤多次，滤液加水稀释，乙酸乙酯萃取，合并有机相，饱和盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得白色固体标题化合物IN-2d(398mg,收率86％)。
第四步5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-胺IN-2
化合物IN-2d(398mg,0.86mmol)溶于二氯甲烷(6mL)中，加入三氟乙酸(2mL)，室温搅拌1小时，TLC 显示原料反应完全。反应液浓缩，加入饱和碳酸氢钠水溶液，乙酸乙酯萃取，饱和盐水洗涤，无水硫酸钠干燥，浓缩得黄色固体标题化合物IN-2(215mg,粗品)，直接用于下一步。
中间体3
7-(2-氨基-5-氯吡啶-4-基)-2,2-二甲基-2,3-二氢-1H-吡咯嗪-5-甲腈IN-3
Figure PCTCN2021091707-appb-000023
第一步4-溴-1H-吡咯-2-甲醛IN-3b
1H-吡咯-2-甲醛IN-3a(10.0g,105.3mmol)溶于四氢呋喃(100mL)中，氮气保护下，冷却至0℃，加入N-溴代丁二酰亚胺(19.7g,110.5mmol)，保持在0℃下反应30分钟，TLC显示原料消失。反应液浓缩除去有机溶剂，加水稀释，乙酸乙酯萃取，合并有机相，饱和盐水洗涤，无水硫酸钠干燥，浓缩，粗品经硅胶柱纯化得到白色固体标题化合物IN-3b(12.6g,收率69％)。
LC-MS:m/z＝174.0[M+H] +
第二步4-溴-1H-吡咯-2-甲腈IN-3c
化合物IN-3b(5.0g,28.7mmol)溶于水(150mL)中，加入O-羟胺磺酸(11.4g,100.6mmol)，室温搅拌过夜，TLC显示原料消失(原料和产品用醛酮显色剂区分)。反应液冷却至0℃，氢氧化钾溶液(4N)调节pH＝13-14，二氯甲烷萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品经硅胶柱纯化得到白色固体标题化合物IN-3c(4.2g,收率85.0％)。
LC-MS:m/z＝168.9[M-H] -
第三步4-(4-溴-2-氰基-1H-吡咯-1-基)-3,3-二甲基丁酸甲酯IN-3d
化合物IN-3c(1.0g,5.8mmol)分散在N,N-二甲基甲酰胺(15mL)中，室温下加入碳酸钾(1.6g,11.6mmol)和化合物IN-1d(1.7g,8.8mmol)，升温至85℃搅拌过夜，TLC显示原料反应完全。反应液冷却至室温，加水稀释，乙酸乙酯萃取，合并有机相，水洗，饱和盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得到黄色液体标题化合物IN-3d(1.7g,收率97％)。
第四步4-(4-溴-2-氰基-1H-吡咯-1-基)-3,3-二甲基丁酸IN-3e
化合物IN-3d(1.7g,5.7mmol)分散在四氢呋喃(15mL)和甲醇(15mL)中，冷却至0℃，加入氢氧化钠水溶液(3mL,12mmol,4M)，缓慢升至室温搅拌30分钟，TLC显示原料反应完全。反应液浓缩除去有机溶剂，加水稀释，乙酸乙酯萃取，有机相弃掉，水相用稀盐酸(1N)调节pH为酸性，乙酸乙酯萃取，合并有机相，饱和盐水洗，无水硫酸钠干燥，浓缩得黄色油状标题化合物IN-3e(1.4g,粗品)，直接用于下一步。
第五步4-(4-溴-2-氰基-1H-吡咯-1-基)-3,3-二甲基丁酰氯IN-3f
化合物IN-3e(1.4g,粗品)分散在二氯甲烷(30mL)中，室温下加入N,N-二甲基甲酰胺(1mL)，冷却至0℃，滴加草酰氯(980mg,7.7mmol)，滴毕，缓慢升至室温搅拌30分钟，TLC显示原料反应完全(甲醇淬灭点板)。反应液浓缩得黄色油状标题化合物IN-3f(1.5g,粗品)，直接用于下一步。
第六步7-溴-2,2-二甲基-1-氧代-2,3-二氢-1H-吡咯嗪-5-甲腈IN-3g
三氯化铝(1.4g,5.8mmol)分散在二氯甲烷(15mL)中，冷却至0℃，氮气保护下滴加化合物IN-3f(1.5g,粗品)的二氯甲烷(15mL)溶液，滴毕，自然升温至室温搅拌过夜，TLC显示原料反应完全。反应液倒入冰水淬灭，加盐酸(1N)调节pH为酸性，二氯甲烷萃取，合并有机相，饱和盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得白色固体标题化合物IN-3g(900mg,三步收率62％)。
1H NMR(400MHz,CDCl 3)δ7.00(s,1H),4.17(s,2H),1.38(s,6H).
第七步7-溴-1-羟基-2,2-二甲基-2,3-二氢-1H-吡咯嗪-5-甲腈IN-3h
化合物IN-3g(870mg,3.4mmol)分散在甲醇(15mL)中，冷却至0℃，加入硼氢化钠(330mg,8.7mmol)，升至室温搅拌1小时，TLC显示原料反应完全。反应液加水淬灭，浓缩除去甲醇，乙酸乙酯萃取，合并有机相，饱和盐水洗，无水硫酸钠干燥，浓缩得标题化合物IN-3h(1.0g,粗品)，直接用于下一步。
第八步7-溴-2,2-二甲基-2,3-二氢-1H-吡咯嗪-5-甲腈IN-3i
化合物IN-3h(1.0g,粗品)分散在三氟乙酸(20mL)中，冷却至0℃，氮气置换，滴加三乙基硅烷(1.4g,12mmol)，加完0℃搅拌1小时，TLC显示原料反应完全。反应液浓缩，饱和碳酸氢钠水溶液调节pH为碱性，乙酸乙酯萃取，合并有机相，饱和盐水洗，无水硫酸钠干燥，浓缩得黄色液体标题化合物IN-3i(370mg,粗品)，直接用于下一步。
LC-MS:m/z＝239.3[M+H] +
第九步(5-氯-4-(5-氰基-2,2-二甲基-2,3-二氢-1H-吡咯嗪-7-基)吡啶-2-基)亚氨基二碳酸二叔丁酯IN-3j
化合物IN-2c(250mg,粗品)和化合物IN-3i(1.2g,1.6mmol)分散在1,4-二氧六环(5mL)和水(2mL)中，依次加入碳酸钠(220mg,2.1mmol)和Pd(dppf)Cl 2(催化量)，氮气保护下升温至100℃搅拌1小时，TLC显示原料反应完全。反应液冷却至室温，过滤，滤饼乙酸乙酯洗涤，滤液加水稀释，乙酸乙酯萃取，合并有机相，饱和盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得白色固体标题化合物IN-3j(300mg,三步收率26％)。
LC-MS:m/z＝387.2[M+H-Boc] +
第十步7-(2-氨基-5-氯吡啶-4-基)-2,2-二甲基-2,3-二氢-1H-吡咯嗪-5-甲腈IN-3
IN-3j(300mg,0.62mmol)分散在二氯甲烷(6mL)中，加入三氟乙酸(3mL)，室温搅拌1小时，TLC显示原料反应完全。反应液浓缩除，饱和碳酸氢钠水溶液淬灭，乙酸乙酯萃取，合并有机相，饱和盐水洗，无水硫酸钠干燥，浓缩得黄色固体标题化合物IN-3(250mg,粗品)，直接用于下一步。
LC-MS:m/z＝287.1[M+H] +
实施例1
3-(2-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-2-氧代乙基)苯甲酰胺1
Figure PCTCN2021091707-appb-000024
第一步2-(3-溴苯基)乙酸甲酯1b
3-溴苯乙酸1a(10.0g,46.5mmol)溶于甲醇(80mL)中，缓缓滴入浓硫酸(4.6g,46.5mmol)，升温至60℃反应3小时，TLC显示反应完全。反应液冷却至室温，浓缩除去大部分甲醇，加水，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得浅黄色透明液体标题化合物1b(10.8g,粗品)，直接用于下一步。
LC-MS:m/z＝229.0/230.9[M+H] +
第二步2-(3-氰基苯基)乙酸甲酯1c
化合物1b(9.0g,粗品)溶于N-甲基吡咯烷酮(80mL)中，加入氰化锌(9.2g,78.4mmol)和四-三苯基磷钯 (1.15g,1.0mmol)，氮气保护下，升温至160℃反应8小时，TLC显示反应完全。反应液冷却至室温，加水，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得浅黄色透明液体标题化合物1c(5.0g,粗品)，直接用于下一步。
LC-MS:m/z＝176.0[M+H] +
1H NMR(400MHz,CDCl 3)δ7.58-7.51(m,3H),7.44(t,J＝7.6Hz,1H),3.71(s,3H),3.66(s,2H).
第三步2-(3-氨基甲酰苯基)乙酸甲酯1d
化合物1c(5.0g,粗品)溶于二甲基亚砜(50mL)中，加入双氧水(10mL,30％)和碳酸钾(600mg,4.3mmol)，室温反应过夜，TLC显示反应完全。反应液加水，二氯甲烷萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得类白色固体标题化合物1d(5.5g,粗品)，直接用于下一步。
第四步3-甲酰胺基苯乙酸1e
化合物1d(1.0g,粗品)溶于四氢呋喃(5mL)中，依次加入氢氧化钠(416mg,10.4mmol)的水(3mL)溶液和甲醇(1mL)，室温反应1小时，TLC显示反应完全。反应液加水，加盐酸(4N)调节pH＝4-5，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得类白色固体标题化合物1e(600mg,粗品)，直接用于下一步。
LCMS:m/z＝180.1[M+H] +
第五步3-(2-((4-溴-5-氯吡啶-2-基)氨基)-2-氧乙基)苯甲酰胺1g
化合物1e(600mg,粗品)溶于二氯甲烷(10mL)中，加入1-(3-二甲氨基丙基)-3-乙基碳二亚胺(980mg,5.1mmol)，室温搅拌1小时，加入4-溴-5-氯吡啶-2-氨基1f(704mg,3.4mmol)，升温至30℃搅拌2天，TLC显示仍有大量原料剩余。反应液加水，二氯甲烷萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得淡黄色固体标题化合物1g(105mg,粗品)，直接用于下一步。
第六步3-(2-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-2-氧代乙基)苯甲酰胺1
化合物1g(160mg,粗品)溶于1,4-二氧六环(6mL)和水(2mL)的混合溶剂中，室温下依次加入碳酸钠(91mg,0.86mmol)、中间体IN-1(170mg,0.65mmol)和Pd(dppf)Cl 2二氯甲烷络合物(33mg,0.04mmol)，氮气保护下，升温至90℃反应3小时，TLC显示反应完全。反应液加水，二氯甲烷萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，粗品Prep-TLC纯化得白色固体标题化合物1(29mg,六步收率1％)。
LC-MS:m/z＝423.9[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.92(s,1H),8.38(s,1H),8.22(s,1H),8.00(s,1H),7.96(s,1H),7.85(s,1H),7.76(d,J＝7.6Hz,1H),7.49(d,J＝7.6Hz,1H),7.40(t,J＝7.6Hz,1H),7.34(s,1H),3.92(s,2H),3.80(s,2H),2.86(s,2H),1.24(s,6H).(95.31％purity by HPLC)
实施例2
(S)-3-(1-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-1-氧代丙烷-2-基)苯甲酰胺(假设)2-1
(R)-3-(1-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-1-氧代丙烷-2-基)苯甲酰胺(假设)2-2
Figure PCTCN2021091707-appb-000025
第一步2-(3-溴苯基)丙酸甲酯2a
化合物1b(5.0g,21.83mmol)溶于无水四氢呋喃(50mL)中，氮气保护下，降温至-78℃，滴加二异丙基氨基锂(13mL,26mmol,2M四氢呋喃溶液)，加完-60℃下反应1小时，滴加碘甲烷(3.1g,21.84mmol)，加完升至室温反应1小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水 洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得黄色液体标题化合物2a(1.6g,收率30％)。
第二步2-(3-氰基苯基)丙酸甲酯2b
化合物2a(1.7g,6.99mmol)溶于N-甲基吡咯烷酮(10mL)中，室温下加入氰化锌(1.3g,11.07mmol)和四-三苯基磷钯(140mg,0.12mmol)，升温至150℃反应5小时，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得黄色液体标题化合物2b(1.0g,收率77％)。
第三步2-(3-甲酰胺基苯基)丙酸甲酯2c
化合物2b(1.0g,5.28mmol)溶于二甲基亚砜(10mL)中，加入碳酸钾(110mg,0.80mmol)和双氧水(2.0mL,30％)，室温反应1小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得黄色液体标题化合物2c(1.0g,收率91％)。
LC-MS:m/z＝208.2[M+H] +
第四步2-(3-甲酰胺基苯基)丙酸2d
化合物2c(1.0g,4.82mmol)溶于四氢呋喃/甲醇/水(12mL/2mL/6mL)中，加入氢氧化钠(0.5g,12.50mmol)，室温搅拌1小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，丢弃有机相，水相用稀盐酸(1N)调节pH＝3，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得到白色固体标题化合物2d(910mg,粗品)，直接用于下一步。
第五步N-(4-溴-5-氯吡啶-2-基)-2-(3-氰基苯基)丙酰胺2e
化合物2d(241mg,粗品)和化合物1f(373mg,1.80mmol)溶于乙酸乙酯(5mL)中，室温下加入1-丙基磷酸酐(1.8g,2.83mmol,50％乙酸乙酯溶液)和吡啶(455mg,5.75mmol)，升温至85℃反应3小时，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物2e(200mg,两步收率43％)。
LC-MS:m/z＝364.0[M+H] +
第六步N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(3-氰基苯基)丙酰胺2f
化合物2e(250mg,0.68mmol)和中间体IN-1(233mg,0.89mmol)溶于1,4-二氧六环(5mL)和水(2.5mL)中，室温下加入碳酸钾(276mg,2.00mmol)和Pd(dppf)Cl 2二氯甲烷络合物(57mg,0.07mmol)，氮气保护下，升温至100℃反应过夜，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物2f(90mg,收率31％)。
第七步(S)-3-(1-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-1-氧代丙烷-2-基)苯甲酰胺(假设)2-1&(R)-3-(1-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-1-氧代丙烷-2-基)苯甲酰胺(假设)2-2
化合物2f(90mg,0.21mmol)溶于二甲基亚砜(5mL)中，加入碳酸钾(50mg,0.36mmol)和双氧水(1mL,30％)，室温反应1小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体化合物2(81mg,收率88％)，手性拆分(DAICEL AD-H,30*250mm,5um,30mL/min,EtOH:Hexane＝40:60)得标题化合物2-1(RT 34.5min)(13.7mg,收率17％)和标题化合物2-2(RT 39.7min)(16.2mg,收率20％)。
化合物2-1
LC-MS:m/z＝438.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.85(s,1H),8.35(s,1H),8.23(s,1H),7.98(s,2H),7.94(s,1H),7.76(d,J＝7.6Hz,1H),7.56(d,J＝8.0Hz,1H),7.41(t,J＝7.6Hz,1H),7.36(s,1H),4.10(q,J＝7.2Hz,1H),3.94(s,2H),2.88(s,2H),1.46(d,J＝6.8Hz,3H),1.27(s,6H).(98.78％purity by HPLC)
化合物2-2
LC-MS:m/z＝438.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.85(s,1H),8.35(s,1H),8.23(s,1H),7.98(s,2H),7.94(s,1H),7.76(d,J＝7.6Hz,1H),7.56(d,J＝8.0Hz,1H),7.41(t,J＝7.6Hz,1H),7.36(s,1H),4.10(q,J＝7.2Hz,1H),3.94(s,2H),2.88(s,2H),1.46(d,J＝6.8Hz,3H),1.27(s,6H).(98.60％purity by HPLC)
实施例3
3-(2-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-2-氧代乙基)-N-甲基苯甲酰胺3
Figure PCTCN2021091707-appb-000026
第一步间羧基苯乙酸3a
化合物1c(2.0g,11.42mmol)和氢氧化钠(1.83g,45.76mmol)溶于水(20mL)和乙醇(5mL)中，升温至75℃反应过夜，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，丢弃有机相，水相用稀盐酸(1N)调节pH＝3，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得到白色固体标题化合物3a(1.8g,粗品)，直接用于下一步。
第二步3-(2-甲氧基-2-氧代乙基)苯甲酸3b
氯化亚砜(36mg,0.30mmol)加入到化合物3a(1.8g,10.0mmol)的甲醇(5mL)溶液中，室温搅拌过夜，TLC原料消失。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得白色固体标题化合物3b(1.6g,粗品)，直接用于下一步。
1H NMR(400MHz,CDCl 3)δ13.00(s,1H),7.88-7.84(m,2H),7.54-7.44(m,2H),3.79(s,2H),3.63(s,3H).
第三步2-(3-(氯羰基)苯基)乙酸甲酯3c
氯化亚砜(5mL,0.07mmol)加入到化合物3b(600mg,粗品)的甲苯(15mL)溶液中，升温至85℃搅拌3小时，TLC显示原料消失。反应液浓缩得标题化合物3c(656mg,粗品)，直接用于下一步。
第四步2-(3-(甲基氨甲酰)苯基)乙酸甲酯3d
化合物3c(328mg,粗品)和甲胺盐酸盐(125mg,1.85mmol)溶于二氯甲烷(3mL)中，加入三乙胺(0.5mL,3.60mmol)，室温搅拌30分钟，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得无色油状液体标题化合物3d(230mg,粗品)，直接用于下一步。
LC-MS:m/z＝208.0[M+H] +
第五步2-(3-(甲基氨甲酰)苯基)乙酸3e
化合物3d(230mg,粗品)溶于四氢呋喃(3mL)和水(3mL)的混合溶剂中，加入氢氧化钠(67mg,1.67mmol)，室温搅拌过夜，TLC显示反应完全。反应液加水淬灭，稀盐酸(1N)调pH-3，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得白色固体标题化合物3e(180mg,粗品)，直接用于下一步。
第六步3-(2-((4-溴-5-氯吡啶-2-基)氨基)-2-氧代乙基)-N-甲基苯甲酰胺3f
化合物3e(180mg,粗品)和化合物1f(200mg,0.96mmol)溶于乙酸乙酯(20mL)中，室温下加入吡啶(379mg,4.79mmol)，滴加1-丙基磷酸酐(2.05g,3.22mmol,50％乙酸乙酯溶液)，加完室温反应过夜，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，水洗，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物3f(210mg,六步收率28.8％)。
1H NMR(400MHz,DMSO-d 6)δ11.18(s,1H),8.52(s,1H),8.48(s,1H),8.44-8.43(m,1H),7.81(s,1H),7.71(d,J＝7.6Hz,1H),7.48-7.39(m,2H),3.81(s,2H),2.78(d,J＝4.4Hz,3H).
第七步3-(2-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-2-氧代乙基)-N-甲基苯甲酰胺3
化合物3f(100mg,0.26mmol)和中间体IN-1(100mg,0.38mg)溶于1,4-二氧六环/水(2mL/0.5mL)中，室温下加入碳酸钠(40mg,0.38mmol)和Pd(dppf)Cl 2(18mg,0.025mmol)中，氮气保护下，升温至80℃反应两小时，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，水洗，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品Prep-TLC分离纯化得白色固体标题化合物3(32mg,收率29％)。
LC-MS:m/z＝438.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.95(s,1H),8.45-8.43(m,1H),8.38(s,1H),8.22(s,1H),8.00(s,1H),7.82(s,1H),7.71(d,J＝7.6Hz,1H),7.48(d,J＝7.6Hz,1H),7.41(t,J＝8.0Hz,1H),3.92(s,2H),3.80(s,2H),2.86(s,2H),2.78(d,J＝4.8Hz,3H),1.24(s,6H).(95.32％purity by HPLC)
实施例4
N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(3-氰基苯基)乙酰胺4
Figure PCTCN2021091707-appb-000027
第一步N-(4-溴-5-氯吡啶-2-基)-2-(3-氰基苯基)乙酰胺4a
化合物1e(347mg,1.94mmol)溶于乙酸乙酯(10mL)中，室温下加入化合物1f(331mg,1.60mmol)，1-丙基磷酸酐(4.10g,6.44mmol,50％乙酸乙酯溶液)和吡啶(764mg,9.66mmol)，升温至85℃反应2小时，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物4a(537mg,收率68％)。
第二步N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(3-氰基苯基)乙酰胺4
化合物4a(100mg,0.28mmol)溶于1,4-二氧六环(6mL)和水(2mL)中，室温下加入中间体IN-1(112mg,0.43mmol)，碳酸钾(79mg,0.57mmol)和Pd(dppf)Cl 2二氯甲烷络合物(催化量)，氮气保护下，升温至95℃反应过夜，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品Prep-TLC分离纯化得白色固体标题化合物4(38mg,收率33％)。
LC-MS:m/z＝406.1[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.95(s,1H),8.38(s,1H),8.19(s,1H),7.99(s,1H),7.79(s,1H),7.74(d,J＝7.6Hz,1H),7.68(d,J＝8.0Hz,1H),7.55(t,J＝8.0Hz,1H),3.92(s,2H),3.85(s,2H),2.95(s,2H),1.24(s,6H).(97.23％purity by HPLC)
实施例5
N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(吡啶-4-基)乙酰胺5
Figure PCTCN2021091707-appb-000028
第一步2-(吡啶-4-基)乙酸5b
吡啶-4-乙酸甲酯5a(2.0g,13.23mmol)溶于四氢呋喃/水(10mL/5mL)中，加入氢氧化钠(1.32g,33.01mmol)，室温下搅拌2小时。TLC显示反应完全。反应液加水淬灭，水相乙酸乙酯萃取，丢弃有机相，水相用稀盐酸(1N)调节pH＝3，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得到白色固体标题化合物5b(1.40g,粗品)，直接用于下一步。
第二步N-(4-溴-5-氯吡啶-2-基)-2-(吡啶-4-基)乙酰胺5c
化合物5b(300mg,粗品)溶于乙酸乙酯(20mL)中，依次加入化合物1f(379mg,1.83mmol)，吡啶(868mg,10.97mmol)，1-丙基磷酸酐(4.66g,7.32mmol,50％乙酸乙酯溶液)，室温搅拌过夜。TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物5c(633mg,收率89％)，
LC-MS:m/z＝326.0[M+H] +
第三步N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(吡啶-4-基)乙酰胺5
化合物5c(100mg,0.31mmol)溶于1,4-二氧六环/水(6mL/2mL)中，室温下加入中间体IN-1(158mg,0.60mmol)，碳酸钾(84mg,0.61mmol)和Pd(dppf)Cl 2二氯甲烷络合物(催化量)，氮气保护下升温至95℃反应过夜。TLC显示反应完全。反应液冷却至室温，加水淬灭，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物5(33mg,收率28.2％)。
LC-MS:m/z＝382.2[M+H] +
1H NMR(400MHz,CDCl 3)δ8.82(s,1H),8.65(s,2H),8.26(s,1H),8.20(s,1H),8.11(s,1H),7.46(s,2H),3.95(s,2H),3.85(s,2H),2.95(s,2H),1.34(s,6H).(97.54％purity by HPLC)
实施例6
N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(吡啶-3-基)乙酰胺6
Figure PCTCN2021091707-appb-000029
第一步3-吡啶乙酸6b
将吡啶-3-乙酸乙酯6a(2.0g,12.11mmol)溶于四氢呋喃和水(10mL/5mL)中，加入氢氧化钠(1.32g,33.01mmol)，室温下搅拌2小时，TLC显示反应完全。反应液加稀盐酸(10.2mL,31.60mmol,3M)中和，浓缩得固体，加入甲醇/二氯甲烷溶液(10％)，过滤去除不溶盐，滤液浓缩得标题化合物6b(1.18g,粗品)，直接用于下一步。
第二步N-(4-溴-5-氯吡啶-2-基)-2-(吡啶-3-基)乙酰胺6c
化合物6b(300mg,粗品)溶于乙酸乙酯(20mL)中，室温下依次加入化合物1f(379mg,1.83mmol)，吡啶(868mg,10.97mmol)和1-丙基磷酸酐(4.66g,7.32mmol,50％乙酸乙酯溶液)，室温下搅拌过夜，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得标题化合物6c(590mg,粗品)，直接用于下一步。
第三步N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(吡啶-3-基)乙酰胺6
化合物6c(100mg，粗品)溶于1,4-二氧六环/水(6mL/2mL)中，氮气保护下，室温下依次加入中间体IN-1(158mg,0.60mmol)，碳酸钾(84mg,0.61mmol)和Pd(dppf)Cl 2二氯甲烷络合物(催化量)，升温至95℃反应过夜，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析得白色固体标题化合物6(33mg,三步收率16％)。
LC-MS:m/z＝382.1[M+H] +
1H NMR(400MHz,CDCl 3)δ8.78(s,1H),8.61(d,J＝4.4Hz,1H),8.42(s,1H),8.23(s,1H),8.21(s,1H),8.10(s,1H),7.89(d,J＝8.0Hz,1H),7.45(dd,J＝7.6Hz,4.8Hz,1H),3.95(s,2H),3.87(s,2H),2.94(s,2H),1.33(s,6H).(97.14％purity by HPLC)
实施例7
N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(6-氰基吡啶-2-基)乙酰胺7
Figure PCTCN2021091707-appb-000030
第一步2-(6-溴吡啶-2-基)乙酸甲酯7c
2-溴-6-甲基吡啶7a(5.0g,29.1mmol)溶于无水四氢呋喃(30mL)中，氮气保护下，降温至-50℃，依次滴加二异丙基氨基锂(39mL,78.0mmol,2M四氢呋喃溶液)，氯甲酸甲酯7b(3.2g,33.9mmol)，滴加完毕后，-50℃搅拌15分钟，TLC显示反应完全。反应液倒入水中，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得淡黄色固体标题化合物7c(1.2g,收率15％)。
LC-MS:m/z＝230.0[M+H] +
1H NMR(400MHz,DMSO-d 6)δ7.52(t,J＝8.0Hz,1H),7.40(d,J＝8.0Hz,1H),7.28(d,J＝8.0Hz,1H),3.84(s,2H),3.82(s,3H).
第二步2-(6-氰基吡啶-2-基)乙酸甲酯7d
化合物7c(1.1g,4.8mmol)溶于N,N-二甲基甲酰胺(10mL)和水(1mL)中，依次加入氰化锌(845mg,7.2mmol)，Pd(dppf)Cl 2(200mg,0.3mmol)和Pd 2(dba) 3(270mg,0.3mmol)，升温至90℃反应3小时，TLC显示反应完全。反应液冷却至室温，倒入水中，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得淡黄色液体标题化合物7d(710mg,收率84％)。
LC-MS:m/z＝177.1[M+H] +
第三步2-(6-氰基吡啶-2-基)乙酸7e
化合物7d(600mg,3.4mmol)溶于四氢呋喃(6mL)中，加入氢氧化钠(136mg,3.4mmol)的水(2mL)溶液和甲醇(2mL)，室温反应1小时，TLC显示反应完全。反应液倒入水中，稀盐酸(2N)调节pH至5-6，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得淡黄色固体标题化合物7e(370mg,粗品)，直接用于下一步。
第四步N-(4-溴-5-氯吡啶-2-基)-2-(6-氰基吡啶-2-基)乙酰胺7f
化合物7e(300mg,粗品)溶于乙酸乙酯(5mL)中，室温下依次加入吡啶(506mg,6.4mmol)，1-丙基磷酸酐(2.8g,4.3mmol，50％乙酸乙酯溶液)，4-溴-5-氯-2-氨基吡啶(294mg,1.4mmol)，升温至85℃搅拌1小时，TLC显示反应完全。反应液冷却至室温，倒入水中，饱和碳酸氢钠溶液调节pH至8-9，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得淡黄色固体标题化合物7f(600mg,粗品)，直接用于下一步。
第五步N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(6-氰基吡啶-2-基)乙酰胺7
化合物7f(155mg,粗品)溶于1,4-二氧六环(5mL)和水(2.5mL)的混合溶剂中，加入中间体IN-1(149mg,0.57mmol)，碳酸钾(180mg,1.3mmol)和Pd(dppf)Cl 2的二氯甲烷络合物(33mg,0.03mmol)，氮气保护下，升温至100℃反应过夜，TLC显示反应完全。反应液冷却至室温，倒入水中，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩得白色固体标题化合物7(70mg,收率39％)。
LC-MS:m/z＝407.1[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.98(s,1H),8.39(s,1H),8.19(s,1H),8.02-8.06(m,1H),8.00(s,1H),7.95(d,J＝8.0Hz,1H),7.76(d,J＝8.0Hz,1H),4.07(s,2H),3.92(s,2H),2.85(s,2H),1.24(s,6H).(99.04％purity by HPLC)
实施例8
2-(3-乙酰氨基苯基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)乙酰胺8
Figure PCTCN2021091707-appb-000031
第一步2-(3-乙酰氨基苯基)乙酸甲酯8a
化合物1b(1.5g,粗品)溶于1,4-二氧六环(20mL)中，室温下依次加入碳酸铯(8.5g,26.1mmol)、乙酰胺(0.8g,13.1mmol)、Pd 2(dba) 3(270mg,0.3mmol)和Xphos(170mg,0.3mmol)，氮气保护下，升温至100℃反应2小时，TLC显示反应完全。反应液冷却至室温，加水，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得淡黄色液体标题化合物8a(450mg,两步收率33％)。
LCMS:m/z＝208.1[M+H] +
第二步2-(3-乙酰氨基苯基)乙酸8b
化合物8a(450mg,2.2mmol)溶于四氢呋喃(5mL)中，加入氢氧化钠(170mg,4.2mmol)的水(3mL)溶液和甲醇(1mL)，室温反应1小时，TLC显示反应完全。反应液加水，稀盐酸(4N)调节pH＝4-5，乙酸乙酯萃 取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得类白色固体标题化合物8b(250mg,收率60％)。
1H NMR(400MHz,DMSO-d 6)δ12.53-12.15(m,1H),9.91(s,1H),7.52-7.45(m,2H),7.31-7.13(m,1H),6.91(d,J＝7.6Hz,1H),3.51(s,2H),2.02(d,J＝7.8Hz,3H).
第三步2-(3-乙酰氨基苯基)-N-(4-溴-5-氯吡啶-2-基)乙酰胺8c
化合物8b(500mg,2.6mmol)溶于乙酸乙酯(10mL)中，依次加入吡啶(0.8g,10.1mmol)、化合物1f(505mg,2.4mmol)和1-丙基磷酸酐(0.8g,10.4mmol,50％乙酸乙酯溶液)，室温搅拌过夜，TLC显示仍有原料剩余。反应液加水，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得到淡黄色固体标题化合物8c(180mg,收率18％)。
LC-MS:m/z＝381.9[M+H] +
第四步2-(3-乙酰氨基苯基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)乙酰胺8
化合物8c(180mg,0.47mol)溶于1,4-二氧六环(6mL)和水(2mL)的混合溶剂中，室温下依次加入碳酸钠(100mg,0.94mmol)、中间体IN-1(186mg,0.65mmol)和Pd(dppf)Cl 2二氯甲烷络合物(41mg,0.05mmol)，氮气保护下，升温至90℃反应3小时，TLC显示反应完全。反应液冷却至室温，缓缓倒入水中，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化，Prep-TLC纯化得到白色固体标题化合物8(22mg,收率11％)。
LC-MS:m/z＝438.0[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.87(s,1H),9.91(s,1H),8.37(s,1H),8.23(s,1H),8.00(s,1H),7.55(s,1H),7.47(d,J＝8.0Hz,1H),7.23(t,J＝8.0Hz,1H),7.01(d,J＝7.6Hz,1H),3.93(s,2H),3.71(s,2H),2.87(s,2H),2.02(s,3H),1.25(s,6H).(95.20％purity by HPLC)
实施例9
N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(3-(2-氰基乙酰氨基)苯基)乙酰胺9
Figure PCTCN2021091707-appb-000032
第一步2-(3-((叔丁氧羰基)氨基)苯基)乙酸甲酯9a
化合物1b(1.0g,4.36mmol)和氨基甲酸叔丁酯(0.77g,6.57mmol)溶于1,4-二氧六环(20mL)中，室温下依次加入碳酸铯(2.85g,8.75mmol)，Pd 2(dba) 3(120mg,0.13mmol)和Xantphos(75mg,0.13mmol)，氮气保护下，升温至100℃反应5小时，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得浅黄色透明液体标题化合物9a(625mg,收率54％)。
LC-MS:m/z＝283.2[M+Na] +
第二步2-(3-((叔丁氧羰基)氨基)苯基)乙酸9b
化合物9a(625mg,2.36mmol)溶于甲醇/水(10mL/3mL)中，加入氢氧化钠(141mg,3.53mmol)，室温下反应2小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，丢弃有机相，水相用稀盐酸(1N)调节pH＝3，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩得到浅黄色透明液体标题化合物9b(666mg,粗品)，直接用于下一步。
LC-MS:m/z＝274.1[M+Na] +
第三步(3-(2-((4-溴-5-氯吡啶-2-基)氨基)-2-氧代乙基)苯基)氨基甲酸叔丁酯9c
化合物9b(666mg,粗品)溶于乙酸乙酯(30mL)中，室温下依次加入化合物1f(458mg,2.21mmol)，1-丙基磷酸酐(5.63g,8.85mmol,50％乙酸乙酯溶液)和吡啶(1.05g,13.27mmol)，室温反应过夜，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品 硅胶柱层析分离纯化得白色固体标题化合物9c(830mg,两步收率80％)。
LC-MS:m/z＝442.0[M+H] +
第四步(3-(2-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-2-氧代乙基)苯基)氨基甲酸叔丁酯9d
化合物9c(200mg,0.45mmol)和中间体IN-1(178mg,0.68mmol)溶于1,4-二氧六环(10mL)和水(3mL)中，室温下加入碳酸钾(125mg,0.90mmol)和Pd(dppf)Cl 2(催化量)，氮气保护下，升温至95℃反应过夜，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物9d(78mg,收率35％)。
LC-MS:m/z＝496.2[M+H] +
第五步2-(3-氨基苯基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)乙酰胺9e
化合物9d(78mg,0.16mmol)溶于二氯甲烷(6mL)中，加入三氟乙酸(1mL)，室温反应1小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，丢弃有机相，水相用饱和碳酸钠水溶液调节pH＝9，乙酸乙酯萃取，合并有机相，食盐水洗涤，无水硫酸钠干燥，浓缩得到白色固体标题化合物9e(44mg,收率70％)。
LC-MS:m/z＝396.2[M+H] +
第六步N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(3-(2-氰基乙酰氨基)苯基)乙酰胺9
化合物9e(44mg,0.11mmol)溶于二氯甲烷(5mL)中，加入氰基乙酸(14mg,0.16mmol)和EDCl(32mg,0.17mmol)，室温下搅拌2小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品Prep-TLC分离纯化得白色固体标题化合物9(27.9mg,收率54％)。
LC-MS:m/z＝463.1[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.89(s,1H),10.31(s,1H),8.37(s,1H),8.22(s,1H),8.00(s,1H),7.52(s,1H),7.45(d,J＝7.8Hz,1H),7.29(t,J＝7.2Hz,1H),7.07(d,J＝8.0Hz,1H),3.92(s,2H),3.88(s,2H),3.73(s,2H),2.86(s,2H),1.24(s,6H).(99.49％purity by HPLC)
实施例10
2-(3-乙酰氨基苯基)-N-(5-氯-4-(5-氰基-2,2-二甲基-2,3-二氢-1H-吡咯嗪-7-基)吡啶-2-基)乙酰胺10
Figure PCTCN2021091707-appb-000033
第一步3-(2-((5-氯-4-(5-氰基-2,2-二甲基-2,3-二氢-1H-吡咯嗪-7-基)吡啶-2-基)氨基)-2-氧乙基)苯基氨基甲酸叔丁酯10a
化合物9b(136mg,0.54mmol)和中间体IN-3(130mg,0.45mmol)溶于乙酸乙酯中，室温下加入1-丙基磷酸酐(1.15g,1.81mmol,50％乙酸乙酯溶液)和吡啶(213mg,2.69mmol)，升温至80℃反应2小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物10a(200mg,收率71％)。
LC-MS:m/z＝520.2[M+H] +
第二步2-(3-氨基苯基)-N-(5-氯-4-(5-氰基-2,2-二甲基-2,3-二氢-1H-吡咯嗪-7-基)吡啶-2-基)乙酰胺10b
化合物10a(200mg,0.38mmol)溶于二氯甲烷(6mL)中，加入三氟乙酸(3mL)，室温反应1小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，丢弃有机相，水相用饱和碳酸钠水溶液调节pH＝9，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩得到白色固体标题化合物10b(152mg,粗品)，直接用于下一步。
第三步2-(3-乙酰氨基苯基)-N-(5-氯-4-(5-氰基-2,2-二甲基-2,3-二氢-1H-吡咯嗪-7-基)吡啶-2-基)乙酰胺10
化合物10b(80mg,粗品)溶于四氢呋喃(8mL)中，加入碳酸钾(39mg,0.28mmol)和乙酸酐(23mg,0.23mmol)，室温反应3小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品Prep-TLC分离纯化得白色固体标题化合物10(62mg,两步收率66％)。
LC-MS:m/z＝462.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.93(s,1H),9.98(s,1H),8.39(s,1H),8.19(s,1H),7.57(s,1H),7.47(d,J＝8.0Hz,1H),7.41(s,1H),7.22(t,J＝8.0Hz,1H),7.00(d,J＝7.6Hz,1H),3.93(s,2H),3.70(s,2H),2.84(s,2H),2.02(s,3H),1.21(s,6H).(99.05％purity by HPLC)
实施例11
(S)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(吡啶-3-基)丙酰胺(假设)11-1
(R)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(吡啶-3-基)丙酰胺(假设)11-2
Figure PCTCN2021091707-appb-000034
第一步2-(吡啶-3-基)丙酸乙酯11a
吡啶-3-乙酸乙酯6a(1.0g,6.05mmol)溶于四氢呋喃(10mL)中，冷却至0℃，加入叔丁醇钾(680mg,6.06mmol)，0℃下反应30分钟，加入碘甲烷(3.70g,26.07mmol)，升至室温反应1小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得黄色油状液体标题化合物11a(600mg,收率55％)。
第二步2-(吡啶-3-基)丙酸11b
化合物11a(0.6g,3.35mmol)溶于甲醇(15mL)和水(5mL)中，加入氢氧化钠(0.4g,10.00mmol)，室温反应1小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，丢弃有机相，水相用稀盐酸(1N)调节pH＝3，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得到白色固体标题化合物11b(0.5g,粗品)，直接用于下一步。
第三步N-(4-溴-5-氯吡啶-2-基)-2-(吡啶-3-基)丙酰胺11c
化合物11b(0.5g,粗品)和化合物1f(0.69g,3.32mmol)溶于乙酸乙酯(20mL)中，加入1-丙基磷酸酐(2.1g,3.30mmol,50％乙酸乙酯溶液)和吡啶(0.78g,9.86mmol)，室温反应2小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物11c(600mg,两步收率53％)。
第四步(S)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(吡啶-3-基)丙酰胺(假设)11-1&(R)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(吡啶-3-基)丙酰胺(假设)11-2
化合物11c(176mg,0.52mmol)和中间体IN-1(150mg,0.57mmol)溶于1,4二氧六环(4mL)和水(2mL)中，室温下加入碳酸钠(82mg,0.77mmol)和Pd(dppf)Cl 2(38mg,0.05mmol)，升温至80℃反应2小时，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体化合物11(44mg,收率22％)，手性拆分(DAICEL AD-H,30*250mm,5um,30mL/min,EtOH:Hexane＝40:60)得标题化合物11-1(RT 31.7min)(16mg,收率36％)和标题化合物11-2(RT 44.2min)(17mg,收率39％)。
化合物11-1
LC-MS:m/z＝396.2[M+H] +
1H NMR(400MHz,CDCl 3)δ9.52(br,1H),9.27(s,1H),8.66(s,1H),8.34(s,1H),8.23-8.18(m,2H),8.06(s,1H),7.74-7.66(m,1H),4.53-4.38(m,1H),3.95(s,2H),2.94(s,2H),1.67(d,J＝6.4Hz,3H),1.34(s,6H).(100％purity by HPLC)
化合物11-2
LC-MS:m/z＝396.2[M+H] +
1H NMR(400MHz,CDCl 3)δ8.96(s,1H),8.66-8.60(m,2H),8.21(d,J＝10.4Hz,2H),8.07(s,1H),8.04(d,J＝7.2Hz,1H),7.52-7.50(m,1H),4.17-4.07(m,1H),3.95(s,2H),2.95(s,2H),1.65(d,J＝6.4Hz,3H),1.35(s,6H).(98.85％purity by HPLC)
实施例12
N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(6-甲氧基吡啶-3-基)乙酰胺12
Figure PCTCN2021091707-appb-000035
第一步3-(2,5-二氯吡啶-4-基)-5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑12b
中间体IN-1(230mg,0.88mmol)和2,5-二氯-4-碘吡啶12a(200mg,0.73mmol)溶于1,4-二氧六环(6mL)和水(2mL)中，加入碳酸钾(202mg,1.46mmol)，Pd(dppf)Cl 2二氯甲烷络合物(50mg,0.06mmol)，氮气置换3次，升温至85℃搅拌3小时。TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得淡黄色固体标题化合物12b(108mg,收率52％)。
第二步5-(溴甲基)-2-甲氧基吡啶12d
2-甲氧基-5-甲基吡啶12c(2.0g,16.24mmol)溶于四氯化碳(40mL)中，室温下加入N-溴代丁二酰亚胺(3.18g,17.87mmol)和偶氮二异丁腈(0.27g,1.64mmol)，升温至70℃反应2小时，TLC显示反应完全。反应液浓缩，乙酸乙酯打浆，过滤，滤饼洗涤干燥得到黄色液体标题化合物12d(2.9g,收率88％)。
第三步2-(6-甲氧基吡啶-3-基)乙腈12e
化合物12d(3.0g,14.85mmol)溶于乙腈(30mL)中，室温下加入三甲基氰硅烷(2.50g,25.20mmol)和碳酸钾(2.79g,20.18mmol)，升温至70℃反应2小时，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得无色液体标题化合物12e(450mg,收率21％)。
第四步2-(6-甲氧基吡啶-3-基)乙酰胺12f
化合物12e(350mg,2.36mmol)溶于二甲基亚砜(15mL)中，室温下加入碳酸钾(653mg,4.72mmol)和双氧水(536mg,30％)，升温至50℃反应1小时，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物12f(95mg,收率24.2％)。
1H NMR(400MHz,DMSO-d 6)δ8.00(d,J＝2.0Hz,1H),7.58(dd,J＝2.4Hz,8.8Hz,1H),7.49(br,1H),6.91(br,1H),6.76(d,J＝8.4Hz,1H),3.82(s,3H),3.32(s,2H).
第五步N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(6-甲氧基吡啶-3-基)乙酰胺12
化合物12f(33mg,0.20mmol)和化合物12b(50mg,0.18mmol)溶于1,4-二氧六环(10mL)中，室温下依次加入碳酸铯(118mg,0.36mmol)，Xphos(50mg,0.10mmol)和Pd 2(dba) 3(50mg,0.05mmol)，氮气保护下，升温至100℃反应3小时，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品Prep-TLC纯化得白色固体标题化合物12(13mg,收率16％)。
LC-MS:m/z＝412.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.90(s,1H),8.38(s,1H),8.21(s,1H),8.10(d,J＝2.0Hz,1H),8.00(s,1H),7.67(dd,J＝2.4Hz,8.4Hz,1H),6.80(d,J＝8.4Hz,1H),3.96(s,2H),3.83(s,3H),3.71(s,2H),2.86(s,2H),1.25(s,6H).(98.66％purity by HPLC)
实施例13
(S)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(6-氰基吡啶-2-基)丙酰胺(假设)13-1
(R)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(6-氰基吡啶-2-基)丙酰胺(假设)13-2
Figure PCTCN2021091707-appb-000036
第一步2-(6-溴吡啶-2-基)丙酸甲酯13a
化合物7c(5.4g,23.47mmol)溶于无水四氢呋喃(40mL)中，降温至0℃，加入叔丁醇钾(2.90g,25.8mmol)，0℃反应30分钟，加入碘甲烷(3.33g,23.46mmol)，升至室温反应1小时，TLC显示反应完全。反应液加稀盐酸(1N)淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物13a(3.9g,收率68％)。
第二步2-(6-溴吡啶-2-基)丙酸13b
化合物13a(1.4g,5.74mmol)溶于甲醇(10mL)和水(5mL)中，加入氢氧化钠(0.46g,11.50mmol)，室温反应2小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，丢弃有机相，水相稀盐酸(1N)调节pH＝3，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得到白色固体标题化合物13b(1.1g,粗品)，直接用于下一步。
第三步2-(6-溴吡啶-2-基)丙酰胺13c
化合物13b(1.1g,粗品)溶于N,N-二甲基甲酰胺(15mL)中，依次加入氯化铵(0.77g,14.39mmol)，HATU(2.73g,7.18mmol)和N,N-二异丙基乙胺(1.23g,9.52mmol)，室温搅拌2小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物13c(1.0g,两步收率76％)。
第四步2-(6-氰基吡啶-2-基)丙酰胺13d
化合物13c(1.6g,6.98mmol)溶于N,N-二甲基甲酰胺(20mL)中，室温下加入氰化锌(1.64g,13.97mmol)和四-三苯基膦钯(500mg,0.43mmol)，氮气保护下，升温至100℃反应过夜，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物13d(640mg,收率52％)。
LC-MS:m/z＝176.2[M+H] +
第五步(S)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(6-氰基吡啶-2-基)丙酰胺(假设)13-1&(R)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(6-氰基吡啶-2-基)丙酰胺(假设)13-2
化合物13d(94mg,0.54mmol)和化合物12b(150mg,0.53mmol)溶于1,4-二氧六环(15mL)中，室温下加入碳酸铯(346mg,1.06mmol)，Xphos(50mg,0.10mmol)和Pd 2(dba) 3(50mg,0.05mmol)，氮气保护下，升温至100℃反应3小时，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品Prep-TLC纯化得白色固体化合物13(80mg,收率35％)。手性拆分(DAICEL AD-H,30*250mm,5um,30mL/min,IPA:Hexane＝40:60)得标题化合物13-1(RT 18.0min)(15mg,收率19％)和标题化合物13-2(RT 53.0min)(16mg,收率20％)。
LC-MS:m/z＝421.1[M+H] +
化合物13-1
1H NMR(400MHz,DMSO-d 6)δ10.96(s,1H),8.38(s,1H),8.21(s,1H),8.06(t,J＝7.6Hz,1H),8.00(s,1H),7.95(d,J＝7.2Hz,1H),7.83(d,J＝8.0Hz,1H),4.31(q,J＝7.2Hz,1H),3.94(s,2H),2.88(s,2H),1.51(d,J＝6.8Hz,3H),1.26(s,6H).(99.30％purity by HPLC)
化合物13-2
1H NMR(400MHz,DMSO-d 6)δ10.96(s,1H),8.38(s,1H),8.21(s,1H),8.05(t,J＝7.6Hz,1H),8.00(s,1H),7.95(d,J＝7.2Hz,1H),7.83(d,J＝8.0Hz,1H),4.31(q,J＝7.2Hz,1H),3.93(s,2H),2.88(s,2H),1.51(d,J＝7.2Hz,3H),1.26(s,6H).(100％purity by HPLC)
实施例14
(S)-2-(3-乙酰氨基苯基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺(假设)14-1
(R)-2-(3-乙酰氨基苯基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺(假设)14-2
Figure PCTCN2021091707-appb-000037
第一步2-(3-((叔丁氧羰基)氨基)苯基)丙酸甲酯14a
化合物2a(1.73g,7.12mmol)溶于1,4-二氧六环(30mL)中，室温下加入氨基甲酸叔丁酯(1.25g,10.7mmol)，Pd 2(dba) 3(327mg,0.36mmol)和Xphos(509mg,1.07mmol)，氮气保护下，升温至100℃反应2小时，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得褐色液体标题化合物14a(1.6g,收率80％)。
第二步2-(3-((叔丁氧羰基)氨基)苯基)丙酸14b
化合物14a(1.6g,5.73mmol)溶于乙醇(8mL)和水(4mL)中，加入氢氧化钠(0.46g,11.50mmol)，室温搅拌1小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，丢弃有机相，水相稀盐酸(1N)调节pH＝3，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得到白色固体标题化合物14b(1.0g,粗品)，直接用于下一步。
第三步(3-(1-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-1-氧代丙烷-2-基)苯基)氨基甲酸叔丁酯14c
化合物14b(250mg,粗品)和中间体IN-2(247mg,0.94mmol)溶于乙酸乙酯(8mL)中，室温下加入1-丙基磷酸酐(2.4g,3.77mmol,50％乙酸乙酯溶液)和吡啶(473mg,5.98mmol)，室温反应过夜，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物14c(280mg,收率58％)。
第四步2-(3-氨基苯基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺14d
化合物14c(280mg,0.55mmol)溶于二氯甲烷(6mL)中，加入三氟乙酸(3mL)，室温反应2小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，丢弃有机相，水相饱和碳酸钠水溶液调节pH＝9，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩得到白色固体标题化合物14d(210mg,粗品)，直接用于下一步。
第五步(S)-2-(3-乙酰氨基苯基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺(假设)14-1&(R)-2-(3-乙酰氨基苯基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺(假设)14-2
化合物14d(210mg,粗品)溶于四氢呋喃(10mL)中，加入乙酸酐(72mg,0.71mmol)和碳酸钾(122mg,0.88mmol)，室温反应2小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品Prep-TLC分离纯化得白色固体化合物14(190mg,收率82％)。手性拆分(DAICEL AD-H,30*250mm,5um,30mL/min,IPA:Hexane＝40:60)得标题化合物14-1(RT 13.9min)(60mg,32％)和标题化合物14-2(RT 18.3min)(60mg,收率32％)。
化合物14-1
LC-MS:m/z＝452.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.81(s,1H),9.92(s,1H),8.34(s,1H),8.23(s,1H),7.98(s,1H),7.58(s,1H),7.48(d,J＝7.6Hz,1H),7.23(t,J＝7.6Hz,1H),7.07(d,J＝7.6Hz,1H),4.00(q,J＝7.2Hz,1H),3.93(s,2H),2.88(s,2H),2.01(s,3H),1.39(d,J＝6.8Hz,3H),1.26(s,6H).(99.42％purity by HPLC)
化合物14-2
LC-MS:m/z＝452.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.81(s,1H),9.93(s,1H),8.34(s,1H),8.23(s,1H),7.98(s,1H),7.58(s,1H),7.48(d,J＝8.0Hz,1H),7.23(t,J＝8.0Hz,1H),7.07(d,J＝8.0Hz,1H),4.00(q,J＝6.8Hz,1H),3.93(s,2H),2.88(s,2H),2.01(s,3H),1.39(d,J＝7.2Hz,3H),1.26(s,6H).(99.12％purity by HPLC)
实施例15
(S)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(2-氰基吡啶-4-基)丙酰胺(假设)15-1
(R)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(2-氰基吡啶-4-基)丙酰胺(假设)15-2
Figure PCTCN2021091707-appb-000038
第一步2-(2-溴吡啶-4-基)乙酸甲酯15b
2-溴-4-甲基吡啶15a(10.0g,58.13mmol)溶于无水四氢呋喃(150mL)中，降温至-70℃，缓慢加入二异丙胺基锂(87.2mL,174.4mmol,2M四氢呋喃溶液)，加完-70℃反应1小时，缓慢滴加氯甲酸甲酯(7.14g,75.56mmol)，加完缓慢升至室温反应1小时，TLC显示反应完全。反应液加入饱和氯化铵水溶液淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得黄色液体标题化合物15b(9.5g,收率71％)。
1H NMR(400MHz,DMSO-d 6)δ8.35(d,J＝4.8Hz,1H),7.62(s,1H),7.39(dd,J＝4.2,1.2Hz,1H),3.82(s,2H),3.66(s,3H).
第二步2-(2-溴吡啶-4-基)丙酸甲酯15c
化合物15b(6.0g,26.08mmol)溶于无水四氢呋喃(60mL)中，冷却至0℃，加入叔丁醇钾(2.90g,25.84mmol)，0℃反应30分钟，加入碘甲烷(3.70g,26.07mmol)，升至室温反应1小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得黄色油状液体标题化合物15c(4.4g,收率69％)。
LC-MS:m/z＝245.1[M+H] +
第三步2-(2-溴吡啶-4-基)丙酸15d
化合物15c(1.0g,4.10mmol)溶于四氢呋喃(8mL)和水(4mL)中，加入氢氧化钠(0.33g,8.25mmol)，室温反应1小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，丢弃有机相，水相稀盐酸(1N)调节至pH＝3，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得到白色固体标题化合物15d(365mg,粗品)，直接用于下一步。
LC-MS:m/z＝230.0[M+H] +
第四步2-(2-溴吡啶-4-基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺15e
化合物15d(365mg,粗品)和中间体IN-2(380mg,1.45mmol)溶于乙酸乙酯(20mL)中，加入1-丙基磷酸酐(3.7g,5.81mmol,50％乙酸乙酯溶液)和吡啶(687mg,8.68mmol)，室温反应2小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体标题化合物15e(610mg,收率89％)。
第五步(S)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(2-氰基吡啶-4-基)丙酰胺(假设)15-1&(R)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(2-氰基吡啶-4-基)丙酰胺(假设)15-2
化合物15e(610mg,1.28mmol)溶于N,N-二甲基甲酰胺(30mL)中，室温下加入氰化锌(456mg,3.88mmol)和四-三苯基膦钯(100mg,0.09mmol)，氮气保护下，升温至100℃反应过夜，TLC显示反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得白色固体化合物15(510mg,收率93％)。化合物15(100mg)手性拆分(纳微AD-H, 30*250mm,5um,30mL/min,EtOH:Hexane＝40:60)得标题化合物15-1(RT 14.5min)(36mg,收率36％)和标题化合物15-2(RT 21.5min)(32mg,收率32％)。
化合物15-1
LC-MS:m/z＝421.1[M+H] +
1H NMR(400MHz,DMSO-d 6)δ11.01(s,1H),8.71(s,1H),8.37-7.99(m,4H),7.75(s,1H),4.17(s,1H),3.93(s,2H),2.87(s,2H),1.49(s,3H),1.25(s,6H).(99.74％purity by HPLC)
化合物15-2
LC-MS:m/z＝421.1[M+H] +
1H NMR(400MHz,DMSO-d 6)δ11.00(s,1H),8.71(s,1H),8.38-7.98(m,4H),7.75(s,1H),4.16(s,1H),3.93(s,2H),2.87(s,2H),1.49(s,3H),1.25(s,6H).(98.76％purity by HPLC)
实施例16
(S)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(2-甲氧基吡啶-4-基)丙酰胺(假设)16-1
(R)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(2-甲氧基吡啶-4-基)丙酰胺(假设)16-2
Figure PCTCN2021091707-appb-000039
第一步2-(2-甲氧基吡啶-4-基)乙酸甲酯16b
2-甲氧基-4-甲基吡啶16a(2.0g,16.2mmol)溶于无水四氢呋喃(20mL)中，氮气保护下，降温至-60℃，缓缓加入二异丙基氨基锂(20.4mL,40.8mmol,2M四氢呋喃溶液)，-60℃下搅拌2小时，加入氯甲酸甲酯(2.0g,21.2mmol)，滴加完毕后，室温搅拌1小时。TLC显示反应完全。反应液倒入水中，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析得黄色液体标题化合物16b(1.3g,收率44％)。
LC-MS:m/z＝182.1[M+H] +
1HNMR(400MHz,DMSO-d 6)δ8.11(d,J＝5.2Hz,1H),6.91(dd,J＝1.2,5.2Hz,1H),6.74(d,J＝0.8Hz,1H),3.85(s,3H),3.72(s,2H),3.64(s,3H).
第二步2-(2-甲氧基吡啶-4-基)丙酸甲酯16c
化合物16b(3.75g,20.70mmol)溶于无水四氢呋喃(40mL)中，冷却至0℃，加入叔丁醇钾(2.32g,20.68mmol)，0℃反应30分钟，加入碘甲烷(2.94g,20.71mmol)，升至室温反应1小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析分离纯化得黄色油状液体标题化合物16c(2.3g,收率57％)。
第三步2-(2-甲氧基吡啶-4-基)丙酸16d
化合物16c(500mg,2.56mmol)溶于甲醇(10mL)和水(5mL)中，加入氢氧化钠(210mg,5.25mmol)，室温反应1小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，丢弃有机相，水相稀盐酸(1N)调节pH＝3，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得到白色固体标题化合物16d(180mg,收率39％)。
LC-MS:m/z＝182.1[M+H] +
第四步(S)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(2-甲氧基吡啶-4-基)丙酰胺(假设)16-1&(R)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(2-甲氧基吡啶-4-基)丙酰胺(假设)16-2
化合物16d(180mg,0.99mmol)和中间体IN-2(260mg,0.99mmol)溶于乙酸乙酯(10mL)中，加入1-丙基磷酸酐(2.5g,3.93mmol,50％乙酸乙酯溶液)和吡啶(471mg,5.95mmol)，室温反应2小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅 胶柱层析分离纯化得白色固体化合物16(210mg,收率50％)。手性拆分(纳微AD-H,30*250mm,5um,30mL/min,EtOH:Hexane＝40:60)得标题化合物16-1(14.0min)(30mg,收率14％)和标题化合物16-2(RT 18.0min)(36mg,收率17％)。
化合物16-1
LC-MS:m/z＝426.1[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.90(s,1H),8.36-8.00(m,4H),7.01(s,1H),6.82(s,1H),4.04-4.83(m,6H),2.87(s,2H),1.41(s,3H),1.26(s,6H).(99.64％purity by HPLC)
化合物16-2
LC-MS:m/z＝426.1[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.89(s,1H),8.36(s,1H),8.20(s,1H),8.09(d,J＝4.4Hz,1H),7.98(s,1H),6.99(d,J＝4.0Hz,1H),6.81(s,1H),4.07-3.97(m,1H),3.93(s,2H),3.82(s,3H),2.87(s,2H),1.41(d,J＝6.0Hz,3H),1.25(s,6H).(99.53％purity by HPLC)
实施例17
(S)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(6-(2-羟基丙-2-基)吡啶-2-基)丙酰胺(假设)17-1
(R)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(6-(2-羟基丙-2-基)吡啶-2-基)丙酰胺(假设)17-2
Figure PCTCN2021091707-appb-000040
第一步2-(6-溴吡啶-2-基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺17a
化合物13b(437mg,1.90mmol)和中间体IN-2(500mg,1.90mmol)溶于乙酸乙酯(10mL)中，室温下加入1-丙基磷酸酐(4.86g,7.64mmol,50％乙酸乙酯溶液)和吡啶(905mg,11.44mmol)，升温至50℃反应2小时，TLC监控反应完全。反应液加水，乙酸乙酯萃取，合并有机相，水洗，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得标题化合物17a(700mg,收率52％)。
第二步N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(6-(1-乙氧基乙烯基)吡啶-2-基)丙酰胺17b
化合物17a(430mg,0.91mmol)和三丁基(1-乙氧基乙烯)锡(427mg,1.18mmol)溶于甲苯(10mL)中，室温下加入双三苯基磷钯(64mg,0.09mmol)，氮气保护下，升温至100℃反应过夜，TLC监控原料少量剩余。反应液冷却至室温，加水，乙酸乙酯萃取，合并有机相，水洗，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得标题化合物17b(250mg,收率59％)。
第三步2-(6-乙酰基吡啶-2-基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺17c
化合物17b(250mg,0.54mmol)溶于四氢呋喃(6mL)中，加入稀盐酸(1mL,3N)，室温反应1小时，TLC监控反应完全。反应液加入饱和碳酸氢钠溶液调碱性，乙酸乙酯萃取，合并有机相，水洗，饱和食盐水洗，无水硫酸钠干燥，浓缩得标题化合物17c(240mg,粗品)，直接用于下一步。
第四步(S)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(6-(2-羟基丙-2-基)吡啶-2-基)丙酰胺(假设)17-1&(R)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(6-(2-羟基丙-2-基)吡啶-2-基)丙酰胺(假设)17-2
化合物17c(240mg,粗品)溶于无水四氢呋喃(8mL)中，冷却至0℃，加入甲基溴化镁(0.37mL,1.11mmol,3M)，升至室温反应1小时，TLC监控反应完全。反应液加水，乙酸乙酯萃取，合并有机相，水洗，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得标题化合物17(55mg,两步收率22％)，手性拆分(DAICEL AD-H,30*250mm,5um,30mL/min,IPA:Hexane＝20:80)得标题化合物17-1(RT 31.26min)(3.9mg,收率7.8％)和标题化合物17-2(RT 38.94min)(6.5mg,收率13％)。
化合物17-1
LC-MS:m/z＝454.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.76(s,1H),8.35(s,1H),8.23(s,1H),8.00(s,1H),7.75(t,J＝7.6Hz,1H),7.52(d,J＝7.6Hz,1H),7.27(d,J＝7.6Hz,1H),5.24(s,1H),4.16(q,J＝6.8Hz,1H),3.94(s,2H),2.88(s,2H),1.49(d,J＝7.2Hz,3H),1.42(d,J＝2.0Hz,6H),1.26(s,6H).(99.96％purity by HPLC)
化合物17-2
LC-MS:m/z＝454.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.75(s,1H),8.35(s,1H),8.23(s,1H),8.00(s,1H),7.75(s,1H),7.54(s,1H),7.28(s,1H),5.24(s,1H),4.17(s,1H),3.94(s,2H),2.88(s,2H),1.49-1.43(m,9H),1.26(s,6H).(99.99％purity by HPLC)
实施例18
(S)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(2-(2-羟基丙-2-基)吡啶-4-基)丙酰胺(假设)18-1
(R)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(2-(2-羟基丙-2-基)吡啶-4-基)丙酰胺(假设)18-2
Figure PCTCN2021091707-appb-000041
第一步2-(2-乙酰基吡啶-4-基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺18a
化合物15e(850mg,1.79mmol)和三丁基(1-乙氧基乙烯)锡(840mg,2.33mmol)溶于甲苯(15mL)中，室温下加入Pd(PPh 3) 2Cl 2(126mg,0.18mmol)，氮气保护下，升温至100℃反应过夜，TLC显示反应完全。反应液冷却至室温，加水，乙酸乙酯萃取，合并有机相，无水硫酸钠干燥，浓缩，剩余物加入四氢呋喃溶解，加入稀盐酸(2mL,3N)，室温搅拌1小时，TLC显示反应完全。反应液加入乙酸乙酯萃取，合并有机相，水洗，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得标题化合物18a(493mg,收率62.9％)。
第二步(S)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(2-(2-羟基丙-2-基)吡啶-4-基)丙酰胺(假设)18-1&(R)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)-2-(2-(2-羟基丙-2-基)吡啶-4-基)丙酰胺(假设)18-2
化合物18a(493mg,1.13mmol)溶于无水四氢呋喃(10mL)中，冷却至0℃，加入甲基溴化镁(0.94mL,2.82mmol,3M四氢呋喃溶液)，升至室温反应1小时，TLC显示原料部分剩余。反应液加水，乙酸乙酯萃取，合并有机相，水洗，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得标题化合物18(120mg,收率23％)。手性拆分(DAICEL AD-H,20*250mm,5um,30mL/min,IPA:Hexane＝40:60)得标题化合物18-1(RT 8.86min)(10.0mg,收率1.96％)，标题化合物18-2(RT 12.65min)(28mg,收率5.48％)。
化合物18-1
LC-MS:m/z＝454.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.94(s,1H),8.42(d,J＝4.8Hz,1H),8.36(s,1H),8.21(s,1H),7.98(s,1H),7.71(s,1H),7.24(dd,J＝4.8,1.6Hz,1H),5.23(s,1H),4.08(q,J＝7.2Hz,1H),3.93(s,2H),2.87(s,2H),1.44-1.41(m,9H),1.25(d,J＝8.0Hz,6H).(97.9％purity by HPLC)
化合物18-2
LC-MS:m/z＝454.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.94(s,1H),8.42(d,J＝4.8Hz,1H),8.36(s,1H),8.21(s,1H),7.98(s,1H),7.71(s,1H),7.24(dd,J＝3.6,1.2Hz,1H),5.23(s,1H),4.08(q,J＝7.2Hz,1H),3.93(s,2H),2.87(s,2H),1.44-1.41(m,9H),1.25(s,6H).(99.9％purity by HPLC)
实施例19
(S)-2-([2,3'-联吡啶]-5-基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺(假设)19-1
(R)-2-([2,3'-联吡啶]-5-基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺(假设)19-2
Figure PCTCN2021091707-appb-000042
第一步2-溴-5-(溴甲基)吡啶19b
2-溴-5-甲基吡啶19a(10.0g,58.13mmol)溶于四氯化碳(100mL)中，室温下加入N-溴代丁二酰亚胺(10.9g,61.24mmol)和过氧化二苯甲酰(200mg,0.83mmol)，升温至80℃反应过夜。反应液冷却至室温，过滤，滤液浓缩，粗品硅胶柱层析纯化得标题化合物19b(12g,收率82.2％)。
第二步2-(6-溴吡啶-3-基)-乙腈19c
三甲基氰硅烷(7.1g,71.57mmol)溶于乙腈(200mL)中，室温下加入四丁基氟化铵(18.7g,71.52mmol)，搅拌10分钟，加入化合物19b(12g,47.82mmol)的乙腈(100mL)溶液。室温反应2小时，TLC显示反应完全。反应液加入饱和碳酸氢钠溶液，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析提纯得到标题化合物19c(4.58g,收率48.6％)。
第三步2-(6-溴吡啶-3-基)乙酸甲酯19d
化合物19c(4.58g,23.24mmol)溶于甲醇(50mL)中，滴加二氯亚砜(6.9g,58.00mmol)，室温反应过夜，TLC显示反应完全。反应液浓缩，粗品硅胶柱层析纯化得标题化合物19d(4.8g,收率89.8％)。
第四步2-(6-溴吡啶-3-基)丙酸甲酯19e
化合物19d(4.12g,17.91mmol)溶于四氢呋喃(50mL)中，室温下加入叔丁醇钾(2.42g,21.57mmol)，冷却至0℃，滴加碘甲烷(2.43g,17.12mmol)，滴毕，室温反应1小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析提纯得到标题化合物19e(2.2g,收率50.3％)。
第五步2-(6-溴吡啶-3-基)丙酸19f
化合物19e(1.3g,5.33mmol)溶于甲醇/水(20mL/10mL)中，加入氢氧化钠固体(450mg,11.25mmol)，室温反应2小时，TLC监控原料反应完全。反应液加水淬灭，分液，丢弃有机相，水相用稀盐酸(1N)调节pH为3左右，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩得白色固体标题化合物19f(1.17g,粗品)，直接用于下一步。
第六步2-(6-溴吡啶-3-基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺19g
化合物19f(500mg,粗品)溶于乙酸乙酯(10mL)中，加入中间体IN-2(610mg,2.31mmol)，1-丙基磷酸酐(5.89g,9.26mmol,50％乙酸乙酯溶液)和吡啶(1.1g,13.91mmol)，室温反应2小时，TLC监控原料反应完全。反应液加水淬灭，分液，水相乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，粗品经硅胶柱层析纯化得到标题化合物19g(670mg,两步收率62.0％)。
第七步(S)-2-([2,3'-联吡啶]-5-基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺(假设)19-1&(R)-2-([2,3'-联吡啶]-5-基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺(假设)19-2
氮气保护下，将化合物19g(100mg,0.21mmol)、3-吡啶硼酸(31mg,0.25mmol)、Pd(dppf)Cl 2二氯甲烷络合物(17mg,0.02mmol)和碳酸钠(45mg,0.42mmol)溶于1,4-二氧六环(5mL)/水(1mL)的混合溶液中，氮气置换3次，加热至100℃搅拌3小时，TLC监控反应完全。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，水洗，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品经Prep-TLC纯化得标题化合物19(71mg,收率71.5％)。经手性拆分(DAICEL AD-H,20*250mm,5um,30mL/min,IPA:Hexane＝40:60)得到化合物19-1(RT 28.48min)(25mg,收率25.2％)和化合物19-2(RT 46.28min)(28mg,收率28.2％)。
化合物19-1
LC-MS:m/z＝473.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.96(s,1H),9.23(d,J＝1.6Hz,1H),8.73(d,J＝2.0Hz,1H),8.62(dd,J＝4.8,1.6Hz,1H),8.41-8.38(m,1H),8.36(s,1H),8.22(s,1H),8.04(d,J＝8.4Hz,1H),7.98(s,1H),7.93(dd,J＝8.4,2.4Hz,1H),7.51(dd,J＝7.2,4.8Hz,1H),4.16(q,J＝7.2Hz,1H),3.93(s,2H),2.88(s,2H),1.51(d,J＝7.2Hz,3H),1.26(s,6H).(99.81％purity by HPLC)
化合物19-2
LC-MS:m/z＝473.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.96(s,1H),9.23(d,J＝1.2Hz,1H),8.73(d,J＝2.0Hz,1H),8.62(dd,J＝3.6,1.2Hz,1H),8.41-8.39(m,1H),8.36(s,1H),8.22(s,1H),8.04(d,J＝8.0Hz,1H),7.98(s,1H),7.93(dd,J＝8.0,2.0Hz,1H),7.52(dd,J＝7.6,5.2Hz,1H),4.16(q,J＝7.2Hz,1H),3.93(s,2H),2.88(s,2H),1.51(d,J＝7.2Hz,3H),1.26(s,6H).(99.89％purity by HPLC)
实施例20
(S)-N-((5-(1-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-1-氧代丙烷-2-基)-[2,3'-联吡啶]-6'-基)甲基)丙烯酰胺(假设)20-1
(R)-N-((5-(1-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-1-氧代丙烷-2-基)-[2,3'-联吡啶]-6'-基)甲基)丙烯酰胺(假设)20-2
Figure PCTCN2021091707-appb-000043
第一步2-氰基-5-吡啶硼酸20b
5-溴-2-氰基吡啶20a(5.0g,27.32mmol)和联硼酸频那醇酯(13.9g,54.74mmol)分散在1,4-二氧六环(50mL)中，室温下加入乙酸钾(5.4g,55.02mmol)和Pd(dppf)Cl 2(500mg,0.68mmol)，氮气保护下，升温至100℃反应2小时，TLC显示反应完全。反应液冷却至室温，加水淬灭，分液，水相乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品经硅胶柱层析纯化得标题化合物20b(3.5g,收率87％)。
第二步(6-(((叔丁氧基羰基)氨基)甲基)吡啶-3-基)硼酸20c
化合物20b(3.5g,23.66mmol)溶于甲醇(40mL)中，加入二碳酸二叔丁酯(6.7g,30.70mmol)和钯/碳(350mg,10％)，氢气氛围下室温反应2小时，TLC显示反应完全。反应液垫硅藻土过滤，滤液浓缩得标题化合物20c(4.8g,粗品)，直接用于下一步。
第三步((5-(1-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-1-氧代丙烷-2-基)-[2,3'-联吡啶]-6'-基)甲基)氨基甲酸叔丁酯20d
化合物19g(450mg,0.95mmol)溶于1,4-二氧六环(20ml)与水(4mL)混合溶剂中，室温下加入化合物20c(335mg,粗品)、Pd(dppf)Cl 2(69mg,0.09mmol)和碳酸钠(200mg,1.89mmol)，氮气置换3次，升温至100℃反应5小时，TLC监控原料反应完全。反应液加水淬灭，分液，水相乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，粗品硅胶柱层析纯化得到淡黄色油状物标题化合物20d(128mg,收率22％)。
第四步2-(6'-(氨基甲基)-[2,3'-联吡啶]-5-基)-N-(5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)丙酰胺20e
化合物20d(128mg,0.21mmol)溶于二氯甲烷(5mL)中，加入三氟乙酸(1mL)室温反应1小时，TLC监控原料反应完全。反应液加水，饱和碳酸钠溶液调节pH＝8左右，乙酸乙酯萃取，合并有机相，饱和食盐 水洗，无水硫酸钠干燥，浓缩得到标题化合物20e(108mg,粗品)，直接用于下一步。
第五步(S)-N-((5-(1-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-1-氧代丙烷-2-基)-[2,3'-联吡啶]-6'-基)甲基)丙烯酰胺(假设)20-1&(R)-N-((5-(1-((5-氯-4-(5,5-二甲基-5,6-二氢-4H-吡咯并[1,2-b]吡唑-3-基)吡啶-2-基)氨基)-1-氧代丙烷-2-基)-[2,3'-联吡啶]-6'-基)甲基)丙烯酰胺(假设)20-2
化合物20e(108mg,粗品)溶于二氯甲烷(2mL)和饱和碳酸氢钠水溶液(2mL)的混合体系中，冷却至0℃，滴加丙烯酰氯(14.4mg,0.16mmol)的二氯甲烷(5mL)溶液，室温反应20分钟，TLC监控原料反应完全。反应液加水，分液，水相二氯甲烷萃取，合并有机相，无水硫酸钠干燥，浓缩，粗品经Prep-TLC分离得到标题化合物20(60mg,两步收率51％)。经手性拆分(纳微AD-H,30*250mm,5um,30mL/min,IPA:Hexane＝40:60)得化合物20-1(RT 16.57min)(8.0mg,收率6.9％)和化合物20-2(RT 22.46min)(11mg,收率9.4％)。
化合物20-1
LC-MS:m/z＝556.3[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.95(s,1H),9.16(d,J＝1.6Hz,1H),8.78(t,J＝5.8Hz,1H),8.72(d,J＝2.0Hz,1H),8.41(dd,J＝8.0,2.0Hz,1H),8.36(s,1H),8.22(s,1H),8.02(d,J＝8.0Hz,1H),7.98(s,1H),7.93(dd,J＝8.4,2.0Hz,1H),7.42(d,J＝8.4Hz,1H),6.38(dd,J＝10.4,10.0Hz,1H),6.16(dd,J＝2.0,2.4Hz,1H),5.66(dd,J＝2.0,2.4Hz,1H),4.51(d,J＝5.6Hz,2H),4.17(q,J＝7.2Hz,1H),3.93(s,2H),2.88(s,2H),1.51(d,J＝7.2Hz,3H),1.26(s,6H).(99.21％Purity by HPLC)
化合物20-2
LC-MS:m/z＝556.3[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.95(s,1H),9.17(d,J＝1.6Hz,1H),8.77(t,J＝6.0Hz,1H),8.72(d,J＝2.0Hz,1H),8.40(dd,J＝2.0,2.4Hz,1H),8.36(s,1H),8.22(s,1H),8.03(d,J＝8.2Hz,1H),7.98(s,1H),7.94(dd,J＝2.0,2.4Hz,1H),7.42(d,J＝8.4Hz,1H),6.35(dd,J＝10.0,10.4Hz,1H),6.16(dd,J＝2.0,2.2Hz,1H),5.66(dd,J＝2.0,2.2Hz,1H),4.51(d,J＝5.6Hz,2H),4.15(q,J＝6.8Hz,1H),3.93(s,2H),2.88(s,2H),1.51(d,J＝7.2Hz,3H),1.26(s,6H).(99.93％Purity by HPLC)
实施例21
(S)-N-(4-(5-氰基-2,2-二甲基-2,3-二氢-1H-吡咯嗪-7-基)吡啶-2-基)-2-(6-(2-羟基丙烷-2-基)吡啶-2-基)丙酰胺(假设)21-1
(R)-N-(4-(5-氰基-2,2-二甲基-2,3-二氢-1H-吡咯嗪-7-基)吡啶-2-基)-2-(6-(2-羟基丙烷-2-基)吡啶-2-基)丙酰胺(假设)21-2
Figure PCTCN2021091707-appb-000044
第一步(4-溴吡啶-2-基)亚氨基二碳酸二叔丁酯21b
2-氨基-4-溴吡啶21a(2.0g,11.56mmol)和二碳酸二叔丁酯(6.5g,29.78mmol)溶于二氯甲烷(20mL)中，加入4-二甲氨基吡啶(122mg,0.1mmol)，室温反应过夜，TLC显示反应完全。反应液加水，二氯甲烷萃取，合并有机相，饱和盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析得到白色固体标题化合物21b(3.5g,收率81％)。
第二步(4-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)吡啶-2-基)亚氨基二碳酸二叔丁酯21c
氮气保护下，化合物21b(3.5g,9.38mmol)和联硼酸频那醇酯(3.57g,14.06mmol)溶于1,4-二氧六环(50mL)中，室温下加入醋酸钾(2.30g,23.44mmol)和Pd(dppf)Cl 2(343mg,0.47mmol)，升温至90℃搅拌过夜，TLC显示反应完全。反应液冷却至室温，加水，乙酸乙酯萃取，合并有机相，饱和盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得到白色固体标题化合物21c(2.7g,收率68％)。
第三步(4-(5-氰基-2,2-二甲基-2,3-二氢-1H-吡咯嗪-7-基)吡啶-2-基)亚氨基二碳酸二叔丁酯21d
氮气保护下，化合物21c(500mg,1.19mmol)和中间体IN-3i(340mg,1.42mmol)溶于1,4-二氧六环(6mL)和水(2mL)中，室温下加入碳酸钠(254mg,2.40mmol)和Pd(dppf)Cl 2(88mg,0.12mmol)，升温至90℃反应3小时，TLC显示反应完全。反应液冷却至室温，加水，乙酸乙酯萃取，合并有机相，饱和盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得到白色固体标题化合物21d(380mg,收率70％)。
第四步7-(2-氨基吡啶-4-基)-2,2-二甲基-2,3-二氢-1H-吡咯嗪-5-甲腈21e
化合物21d(380mg,1.08mmol)溶于二氯甲烷(9mL)中，加入三氟乙酸(3mL)室温反应30分钟，TLC显示反应完全。反应液加饱和碳酸氢钠水溶液淬灭，二氯甲烷萃取，合并有机相，饱和盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得到白色固体标题化合物21e(220mg,收率79％)。
第五步2-(6-乙酰基吡啶-2-基)丙酸甲酯21f
氮气保护下，化合物13a(3.36g,13.88mmol)溶于甲苯(40mL)中，室温下加入三丁基(1-乙氧基烯)锡(6.52g,18.04mmol)和Pd(PPh 3) 2Cl 2(974mg,1.39mmol)，升温至100℃反应过夜，TLC显示反应完全。反应液冷却至室温，加水稀释，乙酸乙酯萃取，合并有机相，无水硫酸钠干燥，浓缩，剩余物加四氢呋喃溶解，加稀盐酸(3mL,3N)，室温搅拌1小时，TLC显示反应完全。反应液加乙酸乙酯萃取，合并有机相，水洗，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得标题化合物21f(2.27g,收率79.6％)。
第六步2-(6-乙酰基吡啶-2-基)丙酸21g
化合物21f(2.27g,10.93mmol)溶于乙醇(20mL)中，加入氢氧化钠(1.31g,32.8mmol)的水(5mL)溶液，室温反应1小时，TLC显示反应完全。反应液加水稀释，乙酸乙酯萃取，丢弃有机相，水相加稀盐酸(3N)调节pH＝3，二氯甲烷萃取，合并有机相，水洗，饱和食盐水洗，无水硫酸钠干燥，浓缩得标题化合物21g(1.65g,粗品)，直接用于下一步。
第七步2-(6-乙酰基吡啶-2-基)-N-(4-(5-氰基-2,2-二甲基-2,3-二氢-1H-吡咯嗪-7-基)吡啶-2-基)丙酰胺21h
氮气保护下，化合物21g(340mg,粗品)溶于乙酸乙酯(10mL)中，室温下加入化合物21e(260mg,1.35mmol)，1-丙基磷酸酐(3.44g,5.4mmol,50％乙酸乙酯溶液)和三乙胺(818mg,8.1mmol)，升温至60℃反应2小时，TLC显示反应完全。反应液加水稀释，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得标题化合物21h(224mg,两步收率23％)。
第八步(S)-N-(4-(5-氰基-2,2-二甲基-2,3-二氢-1H-吡咯嗪-7-基)吡啶-2-基)-2-(6-(2-羟基丙烷-2-基)吡啶-2-基)丙酰胺(假设)21-1&(R)-N-(4-(5-氰基-2,2-二甲基-2,3-二氢-1H-吡咯嗪-7-基)吡啶-2-基)-2-(6-(2-羟基丙烷-2-基)吡啶-2-基)丙酰胺(假设)21-2
氮气保护下，化合物21h(351mg,0.82mmol)溶于无水四氢呋喃(10mL)中，降温至0℃，滴加甲基溴化镁(0.68mL,2.04mmol,3N四氢呋喃溶液)，升至室温反应1小时，TLC显示反应完全。反应液加水稀释，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得标题化合物21(65mg,收率17.9％)。手性拆分(DAICEL AD-H,20*250mm,5um,30mL/min,IPA:Hexane＝40:60)得化合物21-1(RT 9.96min)(16mg,收率24.6％)和化合物21-2(RT 21.64min)(20mg,收率30.7％)。
化合物21-1
LC-MS:m/z＝444.3[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.59(s,1H),8.22(d,J＝5.2Hz,1H),8.20(s,1H),7.76(t,J＝8.0Hz,1H),7.53(d,J＝7.6Hz,1H),7.50(s,1H),7.29(d,J＝7.6Hz,1H),7.23(dd,J＝5.2,1.2Hz,1H),5.57-4.99(m,1H),4.15(q,J＝6.8Hz,1H),3.90(s,2H),2.96(s,2H),1.50(d,J＝7.2Hz,3H),1.44(s,6H),1.26(d,J＝2.4Hz,6H).(96.98％purity by HPLC)
化合物21-2
LC-MS:m/z＝444.3[M+H] +
1H NMR(400MHz,DMSO-d 6)δ10.59(s,1H),8.22(d,J＝5.2Hz,1H),8.20(s,1H),7.76(t,J＝8.0Hz,1H),7.53(d,J＝7.6Hz,1H),7.50(s,1H),7.28(d,J＝7.6Hz,1H),7.23(d,J＝4.0Hz,1H),5.57-4.99(m,1H), 4.15(q,J＝6.8Hz,1H),3.90(s,2H),2.94(s,2H),1.50(d,J＝7.2Hz,3H),1.44(s,6H),1.26(d,J＝2.4Hz,6H).(98.44％purity by HPLC)
实施例22
(S)-2-([2,3'-联吡啶]-5-基)-N-(5-氯-4-(6,6-二甲基-6,7-二氢-5H-吡咯并[1,2-a]咪唑-3-基)吡啶-2-基)丙酰胺(假设)22-1(R)-2-([2,3'-联吡啶]-5-基)-N-(5-氯-4-(6,6-二甲基-6,7-二氢-5H-吡咯并[1,2-a]咪唑-3-基)吡啶-2-基)丙酰胺(假设)22-2
Figure PCTCN2021091707-appb-000045
第一步3-甲基-2-丁烯酸乙酯22b
钠氢(8.2g,0.21mol,60％)溶于四氢呋喃(100mL)中冷却至0℃，滴加三乙基膦酰乙酸酯22a(50.0g,0.22mol)，搅拌20分钟，加入丙酮(10.0g,0.17mol)，室温搅拌3小时，TLC显示反应完全。反应液加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得到标题化合物22b(13.0g,收率59％)。
1H NMR(400MHz,CDCl 3)δ5.67(s,1H),4.14(q,J＝7.2Hz,2H),2.17(s,3H),1.27(s,6H).
第二步3,3-二甲基-4-硝基丁酸乙酯22c
化合物22b(13.0g,0.10mol)和硝基甲烷(52.0g,0.85mol)溶于乙腈(130mL)中，室温下加入1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(23.2g,0.15mol)，升温至60℃反应过夜。反应液浓缩，稀盐酸(2N)稀释，乙酸乙酯萃取两次，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得到标题化合物22c(8.3g,收率44％)。
1H NMR(400MHz,CDCl 3)δ4.54(s,2H),4.15(q,J＝7.2Hz,2H),2.45(s,2H),1.27(t,J＝7.2Hz,3H),1.17(s,6H).
第三步4-氨基-3,3-二甲基丁酸乙酯22d
化合物22c(8.3g,43.87mmol)溶于甲醇(100mL)中，加入钯/碳(1.0g,10％)，氢气氛围下升温至40℃搅拌过夜。反应液垫硅藻土过滤，滤液浓缩得到标题化合物22d(5.6g,粗品)，直接用于下一步。
第四步4,4-二甲基吡咯烷丁-2-酮22e
化合物22d(1.0g,粗品)溶于甲醇(10mL)中，室温下加入三乙胺(3.18g,31.43mmol)，升温至80℃反应2天。反应液浓缩，加水稀释，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得到标题化合物22e(300mg,两步收率34％)。
第五步4,4-二甲基吡咯烷-2-硫酮22f
化合物22e(300mg,2.65mmol)溶于甲苯(10mL)中，室温下加入劳森试剂(644mg,1.59mmol)，加热至100℃反应2小时。反应液冷却至室温，直接加硅胶拌样硅胶柱层析纯化得到标题化合物22f(120mg,收率35％)。
1H NMR(400MHz,CDCl 3)δ8.26(s,1H),3.37(s,2H),2.70(s,2H),1.19(s,6H).
第六步3,3-二甲基-5-(甲硫基)-3,4-二氢-2H-吡咯22g
化合物22f(120mg,0.93mmol)溶于异丙醇(5mL)中，加入碘甲烷(528mg,3.72mmol)，室温搅拌过夜。反应液过滤，滤饼乙醚洗两次，烘干得到标题化合物22g(160mg,粗品)，直接用于下一步。
1H NMR(400MHz,DMSO-d 6)δ3.71(s,2H),3.09(s,2H),2.73(s,3H),1.16(s,6H).
第七步N-(2,2-二甲氧基乙基)-3,3-二甲基-3,4-二氢-2H-吡咯-5-胺22h
化合物22g(160mg,粗品)溶于乙醇(10mL)中，室温下加入氨基缩甲醛(66mg,0.63mmol)，加热至70℃反应3小时。反应液浓缩得到标题化合物22h(230mg,粗品)，直接用于下一步。
第八步6,6-二甲基-6,7-二氢-5H-吡咯并[1,2-a]咪唑22i
化合物22h(230mg,粗品)溶于1,4-二氧六环(10mL)中，室温下加入盐酸/1,4-二氧六环(2mL,4N)，加热至90℃反应3小时。反应液冷却至室温，加饱和碳酸钠溶液中和，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得到标题化合物22i(60mg,三步收率47.6％)。
1H NMR(400MHz,DMSO-d 6)δ7.02(d,J＝1.2Hz,1H),6.84(d,J＝0.8Hz,1H),3.67(s,2H),2.55(s,2H),1.19(s,6H).
第九步2-([2,3'-联吡啶]-5-基)丙酸甲酯22j
化合物19e(2.9g,11.88mmol)溶解在1,4二氧六环(25mL)和水(5mL)中，加入3-吡啶硼酸(1.47g,11.96mmol)，室温下加入碳酸钠(2.53g,23.87mmol)，加热至100℃过夜，TLC监控反应完全。反应液冷却至室温，加水，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得标题化合物22j(1.75g,收率61％)。
第十步2-([2,3'-联吡啶]-5-基)丙酸22k
化合物22j(1.7g,7.02mmol)溶解在四氢呋喃(20mL)中，加入氢氧化钠水溶液(3.6mL,14.4mmol,4M)，室温反应1小时，TLC监控反应完全。反应液浓缩，用稀盐酸(2N)调节pH＝5-6，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得到标题化合物22k(930mg,收率58％)。
第十一步2-([2,3'-联吡啶]-5-基)-N-(4-溴-5-氯吡啶-2-基)丙酰胺22l
化合物22k(800mg,3.50mmol)和4-溴-5-氯-2-氨基吡啶(880mg,4.24mmol)溶于乙酸乙酯(20mL)中，室温下加入1-丙基磷酸酐(8.90g,13.99mmol,50％乙酸乙酯溶液)和三乙胺(2.13g,21.05mmol)，加热至70℃反应2小时。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得到标题化合物22l(1.2g,收率82％)。
LC-MS:m/z＝417.0[M+H] +
第十二步(S)-2-([2,3'-联吡啶]-5-基)-N-(5-氯-4-(6,6-二甲基-6,7-二氢-5H-吡咯并[1,2-a]咪唑-3-基)吡啶-2-基)丙酰胺(假设)22-1&(R)-2-([2,3'-联吡啶]-5-基)-N-(5-氯-4-(6,6-二甲基-6,7-二氢-5H-吡咯并[1,2-a]咪唑-3-基)吡啶-2-基)丙酰胺(假设)22-2
化合物22l(1.2g,2.87mmol)和化合物22i(700mg,5.14mmol)溶于N,N-二甲基苯胺(10mL)中，室温下加入醋酸钯(200mg,0.89mmol)和醋酸钾(1.01g,10.29mmol)，加热至120℃反应过夜。反应液冷却至室温，加水淬灭，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥，浓缩，粗品硅胶柱层析纯化得到标题化合物22(120mg,收率9％)。手性拆分(纳微OD-H,30*250mm,5um,30mL/min,IPA:Hexane＝40:60)得化合物22-1(RT 15.09min)(48mg,收率3.5％)和化合物22-2(RT 24.06min)(62mg,收率4.6％)。
化合物22-1
LC-MS:m/z＝473.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ11.06(s,1H),9.23(s,1H),8.74(s,1H),8.62(d,J＝1.2Hz,1H),8.43-8.39(m,2H),8.26(s,1H),8.04(d,J＝8.0Hz,1H),7.94(d,J＝6.8Hz,1H),7.49(m,2H),4.16(q,J＝6.4Hz 1H),3.89(s 2H),2.70(s,2H),1.51(d,J＝6.4Hz,3H),1.23(s,6H).(98.39％purity by HPLC)
化合物22-2
LC-MS:m/z＝473.2[M+H] +
1H NMR(400MHz,DMSO-d 6)δ11.09(s,1H),9.23(s,1H),8.74(s,1H),8.62(d,J 1＝1.2Hz,1H),8.46-8.37(m,2H),8.27(s,1H),8.03(d,J＝8.0Hz,1H),7.94(d,J＝2.2Hz,1H),7.54(d，J＝12.4Hz,2H),4.18(q,J＝6.4Hz 1H),3.91(s 2H),2.74(s,2H),1.52(d,J＝6.4Hz,3H),1.23(s,6H).(97.67％purity by HPLC)
测试例1 化合物对CDK7/CDK9体外酶活性抑制作用的测试
本发明的化合物对体外CDK7/CDK9激酶活性抑制作用的检测通过以下方法进行测定：
1)化合物准备：精确称取化合物，用DMSO(Sigma,D2650)溶解至浓度为10mM备用。稀释化合物至所需的最高浓度的5倍，4倍稀释成6个浓度梯度，使反应体系中化合物终浓度为CDK7:3000、750、188、47、12、3nM；CDK9:100、25、6.25、1.56、0.39、0.098nM。取5ul转至384孔板(Corning,4512)中。
2)激酶反应：在含有化合物的384孔板(Corning,4512)中加入10uL蛋白激酶(CDK7:Eurofilns,14-476M；CDK9:Millipore,14-685M)溶液，室温静置10min；加入ATP(Sigma,A7699)和底物多肽的混合溶液(CDK7:77uM ATP&0.2ug/uL CTD3 peptide(GL Biochem,SY356885)；CDK9:10uM ATP&0.2ug/uL CTD3 peptide(GL Biochem,SY356885))，28℃短暂静置；再每孔再加入25uL终止液终止反应。
3)检测：使用Caliper收集数据。
4)计算：用Graphpad prism 5.0软件根据化合物浓度与对应的信号值计算IC50值。试验结果：见表1。
结论：本发明实施例化合物对CDK7/9激酶活性有明显抑制作用。
测试例2 化合物对Mv4-11细胞增殖抑制的影响
本发明的化合物对体外Mv4-11细胞(ATCC:CRL-9591 TM)增值抑制的作用通过以下方法进行测定：
1)细胞接种：取对数期生长状态良好的Mv4-11细胞以20000个/孔、50uL接种到96孔板中，在37℃、5％CO 2条件下培养2-4h。
2)给药：用含有10％FBS、1％PS的1640培养基稀释化合物：取初始浓度为1mM的化合物0.4uL置于稀释板中，各加入199.6uL上述培养基，四倍梯度稀释，使加入细胞中的终浓度为1000、250、62.5、15.625、3.91、0.98、0.24、0.06nM。依次加入50uL含有化合物的培养基，置于37℃、5％CO 2细胞培养箱中培养48小时。
3)检测：每孔加10uL CCK8(日本同仁,CK04)溶液，37℃、5％CO 2细胞培养箱孵育2小时后，Synergy H1(BioTek)多功能酶标仪读取OD450值。
4)计算：用Graphpad prism 5.0软件根据化合物浓度与对应的信号值计算IC50值。试验结果：见表1。
表1 本发明中化合物对CDK7/9酶活性和细胞Mv4-11的抑制IC 50(nM)
化合物编号 CDK9 CDK7 Mv4-11 化合物编号 CDK9 CDK7 Mv4-11
AZD4573 2.8 109.2 4.2 13-1 44.4 - 148.3
1 3.0 96 7.4 13-2 3.0 328 4.8
2-1 - - ＞1000 14-1 2.3 - 10.1
2-2 2.7 19 1.6 14-2 - - 136.2
3 4.0 103 3.9 15-1 5.9 - 11.2
4 - - 10.7 15-2 - - 160.9
5 - - 26.0 16-1 3.4 - 6.4
6 3.1 197 9.9 16-2 - - 468.9
7 1.7 118 8.2 18-2 3.0 74.0 25.0
8 3.4 116 19.6 19-1 - - 13.9
9 - - 13.0 20-1 8.4 25.1 3.7
11-1 - - 893.1 20-2 - - 849.8
11-2 2.9 - 13.0 22-1 - - 2.6
12 5.2 - 12.2 22-2 - - 78.1
结论：本发明化合物对CDK9具有明显的抑制作用。
测试例3 化合物对Mv4-11细胞中CDK7/CDK9信号通路的测定
本发明的化合物对体外Mv4-11细胞中CDK7/CDK9蛋白下游RNA pol II Ser2/5的抑制的作用通过以下方法进行测定：
1)细胞接种：取对数期生长状态良好的Mv4-11细胞以2*105个/孔接种到六孔板中，在37℃、5％CO2条件下培养过夜。
2)给药：用含有10％FBS、1％PS 2mL 1640的培养基稀释化合物。向过夜培养的细胞中加入2uL含有化合物的培养基，置于37℃、5％CO 2细胞培养箱中培养6小时。
3)蛋白提取、定量：收集细胞悬液、1000g离心5min，弃细胞培养基，加入PBS重悬、离心；反复3次，吸干残留液体，每孔加80uL细胞裂解液置于冰上，摇床晃动10分钟，12000g离心5min，收集上清，即为总蛋白溶液；BCA法测蛋白浓度。
4)12％SDS-PAGE电泳检测，后100V电压转膜3h，封闭液(Beyotime:P0235)封闭15min，TBST(Sangon Biotech：C520002)洗膜三次，一抗(目的蛋白CST:13499,Abcam:ab193467；内参Beyotime:AF1186)4℃孵育过夜；TBST洗膜，三次；二抗(Beyotime:A0208)室温孵育1h；TBST洗膜，三次；ECL(Tanon：180-501)曝光、显色。
化合物2-2、3、11-2、13-1、13-2和AZD4573对RNA pol II Ser2/5的磷酸化作用结果见图1。
结论：本发明化合物如2-2、3、11-2和13-2对急性髓系白血病细胞株(acute myelocytic leukemia,AML)Mv4-11中CDK7蛋白下游RNA pol II Ser5的磷酸化有明显的抑制作用；化合物如2-2、11-2和13-1对CDK9蛋白下游RNA pol II Ser2的磷酸化有明显的抑制作用。
以上仅为本发明的实施方式，其描述较为具体和详细，但并不能因此而理解为对本发明专利范围的限制。应当指出的是，对于本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进，这些均属于本发明的保护范围。

Claims (10)

  1. 一种吡啶乙酰胺类衍生物、其药学上可接受的盐、其互变异构体或其立体异构体，其特征在于，所述吡啶乙酰胺类衍生物的结构如式(I)所示：
    Figure PCTCN2021091707-appb-100001
    其中：
    R 1选自氢、卤素、氰基、取代或未取代的C 1-C 3的烷基或取代或未取代的C 1-C 3的烷氧基，所述“取代”指任选被1-3个卤素取代；
    R 21和R 22分别独立的选自氢、卤素、羟基、氰基、氨基、取代或未取代的C 1-C 3烷基以及取代或未取代的C 1-C 3烷氧基，其中，此处取代是指任选被1-3个卤素、羟基、氰基或氨基取代；
    AR 1选自苯基、5-6元的杂芳基、8-10元的稠芳基和8-10元的稠杂芳基，且其中苯基、5-6元的杂芳基、8-10元的稠芳基和8-10元的稠杂芳基任选地进一步被一个或多个R a所取代；
    R a独立地选自C 1-C 3烷基、羟基、卤素、氰基、氨基、C 1-C 3烷氧基、C 3-C 6环烷基、C 3-C 6杂环基、苯基、5-6元的杂芳基、S(O)R b1、S(O) 2R b1、S(O)NH 2、S(O)NHR b1、S(O)NR b1R b2、S(O) 2NH 2、S(O) 2NHR b1、S(O) 2NR b1R b2、NHS(O)R b1、NR b1S(O)R b2、NHS(O) 2R b1、NR b1S(O) 2R b2、C(O)R b1、C(O)OR b1、OC(O)R b1、NHC(O)R b1、NR b1C(O)R b2、NHC(O)OR b1、NR b1C(O)OR b2、C(O)NH 2、C(O)NHR b1、C(O)NR b1R b2，其中的烷基、烷氧基、环烷基、杂环基、苯基、5-6元的杂芳基任选进一步被1-3个烷基、羟基、卤素、氰基、氨基、烷氧基、丙烯酰基或丙烯酰亚甲基所取代；
    R b1和R b2分别独立地选自C 1-C 3的烷基、3-6元的环烷基或杂环基，其中的烷基、环烷基和杂环基任选进一步被1-3个选自烷基、羟基、卤素、氰基、氨基或烷氧基的取代基所取代，或者R b1和R b2连同它们所连接的N原子形成3-7元的杂环基；
    R 3选自：
    Figure PCTCN2021091707-appb-100002
    Figure PCTCN2021091707-appb-100003
    Z为N或CR c；
    R c独立地选自氢、卤素、氰基、C(O)NH 2、C(O)NHR b1、C(O)NR b1R b2、C(O)R b或C 1-C 3的烷基，其中的烷基任选进一步被1-3个选自烷基、羟基、卤素、氰基、氨基或烷氧基的取代基所取代；
    X和Y连同它们附接的原子一起形成5-7元杂环基或环烷基，其中杂环基包括1-2个选自N、O、S的杂原子；该5-7元杂环基或环烷基是饱和的或者是部分饱和的而且其中的环碳或环S原子任选进一步被1-3个R d取代；
    R d独立地选自卤素、羟基、氰基、＝O或C 1-C 3的烷基，其中的烷基任选进一步被1-3个选自烷基、羟基、卤素、氰基、氨基或烷氧基的取代基所取代。
  2. 如权利要求1所述的吡啶乙酰胺类衍生物、其药学上可接受的盐、其互变异构体或其立体异构体，其特征在于，
    所述吡啶乙酰胺类衍生物的结构如式(Ⅱ)所示：
    Figure PCTCN2021091707-appb-100004
    其中，R 1、R 21、R 22、AR 1和R c具有与权利要求1相同的限定范围。
  3. 如权利要求1所述的吡啶乙酰胺类衍生物、其药学上可接受的盐、其互变异构体或其立体异构体，其特征在于，所述吡啶乙酰胺类衍生物的结构如式(III)所示：
    Figure PCTCN2021091707-appb-100005
    其中，R 1、R 21、R 22、AR 1和R c具有与权利要求1相同的限定范围。
  4. 如权利要求1所述的吡啶乙酰胺类衍生物、其药学上可接受的盐、其互变异构体或其 立体异构体，其特征在于，所述吡啶乙酰胺类衍生物的结构如式(IV)所示：
    Figure PCTCN2021091707-appb-100006
    其中，R 1、R 21、R 22和AR 1具有与权利要求1相同的限定范围。
  5. 如权利要求1所述的吡啶乙酰胺类衍生物、其药学上可接受的盐、其互变异构体或其立体异构体，其特征在于，所述吡啶乙酰胺类衍生物的结构如式(V)所示：
    Figure PCTCN2021091707-appb-100007
    其中，R 1、R 21、R 22和AR 1具有与权利要求1相同的限定范围。
  6. 如权利要求1所述的吡啶乙酰胺类衍生物、其药学上可接受的盐、其互变异构体或其立体异构体，其特征在于，所述吡啶乙酰胺类衍生物选自如下结构的任意一种：
    Figure PCTCN2021091707-appb-100008
    Figure PCTCN2021091707-appb-100009
    Figure PCTCN2021091707-appb-100010
    Figure PCTCN2021091707-appb-100011
  7. 一种如权利要求1-6中任一项所述的吡啶乙酰胺类衍生物、其药学上可接受的盐、其互变异构体或其立体异构体的制备方法，其选自如下三种方法中的一种：
    方法一、
    Figure PCTCN2021091707-appb-100012
    方法二、
    Figure PCTCN2021091707-appb-100013
    方法三、
    Figure PCTCN2021091707-appb-100014
    其中，W为
    Figure PCTCN2021091707-appb-100015
    X为卤素；R 1、AR 1、R 21、R 22和R 3具有与权利要求1相同的限定范围。
  8. 一种药物组合物，其特征在于，所述药物组合物包括如权利要求1-6中任一项所述的吡啶乙酰胺类衍生物、其药学上可接受的盐、其互变异构体或其立体异构体；优选地，所述药物组合物还包括可药用载体和/或赋形剂。
  9. 如权利要求1-6中任一项所述的吡啶乙酰胺类衍生物、其药学上可接受的盐、其互变异构体或其立体异构体、或如权利要求8所述的药物组合物在制备用于治疗癌症药物或在制备CDK家族抑制剂中的用途；
    优选地，所述癌症为血液癌，进一步优选为急性髓细胞白血病、多发性骨髓瘤、慢性淋巴细胞性白血病、滤泡性淋巴瘤或实体瘤；更进一步优选地，所述实体次瘤为乳腺癌、前列腺癌、卵巢癌、肝细胞癌、胰腺癌、肾癌、胃癌、结直肠癌或肺癌。
  10. 一种治疗癌症的方法，该方法是通过向患有癌症的受试者给予一个有效量的如权利要求1-6中任一项所述的化合物进行的。
PCT/CN2021/091707 2020-05-12 2021-04-30 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途 WO2021227906A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP21804225.7A EP4140997A4 (en) 2020-05-12 2021-04-30 PYRIDINE ACETAMIDE DERIVATIVE AS CDK INHIBITOR, PREPARATION METHOD AND USE THEREOF
JP2022569623A JP7451765B2 (ja) 2020-05-12 2021-04-30 Ｃｄｋ阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途
US17/924,720 US20230219961A1 (en) 2020-05-12 2021-04-30 Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010398063.2 2020-05-12
CN202010398063 2020-05-12

Publications (1)

Publication Number Publication Date
WO2021227906A1 true WO2021227906A1 (zh) 2021-11-18

Family

ID=76929837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/091707 WO2021227906A1 (zh) 2020-05-12 2021-04-30 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途

Country Status (5)

Country Link
US (1) US20230219961A1 (zh)
EP (1) EP4140997A4 (zh)
JP (1) JP7451765B2 (zh)
CN (2) CN113173924B (zh)
WO (1) WO2021227906A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115650895A (zh) * 2022-10-20 2023-01-31 上海瑞合达医药科技有限公司 一种3,3-二甲基吡咯烷-2-酮的简便合成方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101282761A (zh) * 2005-08-04 2008-10-08 西特里斯药业公司 作为sirtuin调节剂的苯并咪唑衍生物
WO2015025018A1 (en) * 2013-08-23 2015-02-26 Boehringer Ingelheim International Gmbh New bis-amido pyridines
CN105120862A (zh) * 2013-01-08 2015-12-02 萨穆梅德有限公司 Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用
WO2017001354A1 (en) 2015-06-29 2017-01-05 Astrazeneca Ab Polycyclic amide derivatives as cdk9 inhibitors
WO2018192273A1 (zh) 2017-04-19 2018-10-25 上海炯烁医药科技有限公司 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂
WO2019024876A1 (zh) * 2017-08-04 2019-02-07 上海和誉生物医药科技有限公司 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用
WO2019119145A1 (en) * 2017-12-21 2019-06-27 Ontario Institute For Cancer Research (Oicr) Tricyclic inhibitors of the bcl6 btb domain protein-protein interaction and uses thereof
WO2019154177A1 (zh) 2018-02-12 2019-08-15 恩瑞生物医药科技（上海）有限公司 嘧啶类化合物、其制备方法及其医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0917791B1 (pt) * 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
JP2013521324A (ja) * 2010-03-10 2013-06-10 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
BR112014008222A2 (pt) * 2011-10-06 2017-04-25 Bayer Intelectual Property Gmbh heterociclilpiri (mi) dinilpirazol
CA2901334A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
DE102015209824A1 (de) * 2015-05-28 2016-12-01 BSH Hausgeräte GmbH Vorrichtung und Verfahren zur Bestimmung der Schmutzfracht in einer Spül- oder Waschflotte

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101282761A (zh) * 2005-08-04 2008-10-08 西特里斯药业公司 作为sirtuin调节剂的苯并咪唑衍生物
CN105120862A (zh) * 2013-01-08 2015-12-02 萨穆梅德有限公司 Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用
WO2015025018A1 (en) * 2013-08-23 2015-02-26 Boehringer Ingelheim International Gmbh New bis-amido pyridines
WO2017001354A1 (en) 2015-06-29 2017-01-05 Astrazeneca Ab Polycyclic amide derivatives as cdk9 inhibitors
CN107873028A (zh) * 2015-06-29 2018-04-03 阿斯利康(瑞典)有限公司 用作cdk9抑制剂的多环酰胺衍生物
WO2018192273A1 (zh) 2017-04-19 2018-10-25 上海炯烁医药科技有限公司 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂
WO2019024876A1 (zh) * 2017-08-04 2019-02-07 上海和誉生物医药科技有限公司 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用
WO2019119145A1 (en) * 2017-12-21 2019-06-27 Ontario Institute For Cancer Research (Oicr) Tricyclic inhibitors of the bcl6 btb domain protein-protein interaction and uses thereof
WO2019154177A1 (zh) 2018-02-12 2019-08-15 恩瑞生物医药科技（上海）有限公司 嘧啶类化合物、其制备方法及其医药用途

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"McGraw-Hill Dictionary of Chemical Terms", 1984, MCGRAW-HILLBOOK COMPANY
BERGE ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104
BLAKE ET AL.: "Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer", SCI. SIGNAL., vol. 12, 2019, pages eeav7259, XP055940726, DOI: 10.1126/scisignal.aav7259
BOFFO ET AL.: "CDK9 inhibitors in acute myeloid leukemia", J. EEP. CLIN. CANCER RES., vol. 37, 2018, pages 36, XP055733447, DOI: 10.1186/s13046-018-0704-8
ELIEL,E.WILEN,S.: "Stereochemistry of Organic Compounds", 1994, JOHN WILEY&SONS,INC.
KWAK ET AL.: "Control of transcriptional elongation", ANNU. REV. GENET., vol. 47, 2013, pages 483
See also references of EP4140997A4
ZHANG ET AL.: "CDK7 Inhibition Protentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer", CANCER CELL, vol. 37, 2020, pages 37 - 54
ZHANG ET AL.: "Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer", CELL, vol. 175, 2018, pages 1244 - 1258

Also Published As

Publication number Publication date
CN113173924A (zh) 2021-07-27
EP4140997A4 (en) 2023-09-06
CN113173924B (zh) 2022-07-19
US20230219961A1 (en) 2023-07-13
CN115340555A (zh) 2022-11-15
JP7451765B2 (ja) 2024-03-18
EP4140997A1 (en) 2023-03-01
JP2023515728A (ja) 2023-04-13

Similar Documents

Publication Publication Date Title
WO2020177653A1 (zh) 吡嗪类衍生物及其在抑制shp2中的应用
WO2020156243A1 (zh) Shp2抑制剂及其应用
TWI694078B (zh) 吡咯並三嗪類衍生物、其製備方法及其用途
WO2018166493A1 (zh) 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
TW202108569A (zh) THR-β調節劑及其使用方法
TWI577678B (zh) 雜芳族化合物及其作爲多巴胺ｄ１配位體之用途
WO2021143680A1 (zh) 杂芳基类衍生物及其制备方法和用途
WO2020249079A1 (zh) 一种shp2磷酸酶变构抑制剂
CN115279749B (zh) Shp2抑制剂及其组合物和应用
EP3632903B1 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
WO2021093795A1 (zh) 一种rock抑制剂及其制备方法和用途
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
WO2022135590A1 (zh) 一类嘧啶并杂环类化合物、制备方法和用途
WO2021227906A1 (zh) 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
EP4168411A1 (en) Methods and compounds for restoring mutant p53 function
WO2021227904A1 (zh) 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途
CN108264511B (zh) 杂环类衍生物及其制备方法和其在医药上的用途
WO2023088435A1 (zh) 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用
WO2023274396A1 (zh) 苯并氮杂环类化合物及其在药物中的应用
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
TW201410679A (zh) 哌□并［１，２－ａ］吲哚－１－酮及［１，４］二氮呯并［１，２－ａ］吲哚－１－酮
TWI707853B (zh) 1,2-二氫-1,6-萘啶類衍生物、其製備方法、其藥物組合物及其在醫藥上的用途
CN110105275B (zh) 酰胺类衍生物、其制法与医药上的用途
WO2022089219A1 (zh) 芳基酰胺化合物、包含其的药物组合物及其制备方法和用途
WO2023020512A1 (zh) 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21804225

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022569623

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021804225

Country of ref document: EP

Effective date: 20221124

NENP Non-entry into the national phase

Ref country code: DE